

## REFERENCES

1. Dietitians Association of Australia. Australasian Clinical Practice Guidelines for Nutrition in Cystic Fibrosis. (Dietitians Association of Australia, Australia, 2006). [http://daa.asn.au/wp-content/uploads/2012/09/Guidelines\\_CF-Final.pdf](http://daa.asn.au/wp-content/uploads/2012/09/Guidelines_CF-Final.pdf)
2. Bell, SC & Robinson, PJ. Cystic Fibrosis Standards of Care, Australia. (Cystic Fibrosis Australia, Sydney, Australia, 2008). <http://www.cysticfibrosis.org.au/cfa/standards-of-care>
3. Cystic Fibrosis Association of New Zealand. Standards of Care for Cystic Fibrosis in New Zealand. (Cystic Fibrosis Association of New Zealand, Medical Advisory Committee, Christchurch, New Zealand, 2011). <http://www.cfnz.org.nz/wp-content/uploads/Standard-of-Care-NZ-2011.pdf>
4. Hammons, AJ & Fiese, B. Mealtime interactions in families of a child with cystic fibrosis: a meta-analysis. *J Cyst Fibros* 9, 377-384 (2010).
5. Stark, LJ, Quittner, AL, Powers, SW, Opiari-Arrigan, L, Bean, JA, Duggan, C, *et al.* Randomized clinical trial of behavioral intervention and nutrition education to improve caloric intake and weight in children with cystic fibrosis. *Arch Pediatr Adolesc Med* 163, 915-921 (2009).
6. Powers, SW, Stark, LJ, Chamberlin, LA, Filigno, SS, Sullivan, SM, Lemanek, KL, *et al.* Behavioral and nutritional treatment for preschool-aged children with cystic fibrosis: a randomized clinical trial. *JAMA Pediatr* 169, e150636 (2015).
7. Filigno, SS, Brannon, EE, Chamberlin, LA, Sullivan, SM, Barnett, KA & Powers, SW. Qualitative analysis of parent experiences with achieving cystic fibrosis nutrition recommendations. *J Cyst Fibros* 11, 125-130 (2012).
8. Stark, LJ, Opiari-Arrigan, L, Quittner, AL, Bean, J & Powers, SW. The effects of an intensive behavior and nutrition intervention compared to standard of care on weight outcomes in CF. *Pediatr Pulmonol* 46, 31-35 (2011).
9. Duff, AJ, Wolfe, SP, Dickson, C, Conway, SP & Brownlee, KG. Feeding behavior problems in children with cystic fibrosis in the UK: prevalence and comparison with healthy controls. *J Pediatr Gastroenterol Nutr* 36, 443-447 (2003).
10. Powers, SW, Mitchell, MJ, Patton, SR, Byars, KC, Jelalian, E, Mulvihill, MM, *et al.* Mealtime behaviors in families of infants and toddlers with cystic fibrosis. *J Cyst Fibros* 4, 175-182 (2005).
11. Chinuck, R, Dewar, J, Baldwin, DR & Hendron, E. Appetite stimulants for people with cystic fibrosis. *Cochrane Database Syst Rev* 7, Cd008190 (2014).
12. Thaker, V, Haagensen, AL, Carter, B, Fedorowicz, Z & Houston, BW. Recombinant growth hormone therapy for cystic fibrosis in children and young adults. *Cochrane Database Syst Rev* 5, Cd008901 (2015).
13. Poustie, VJ, Russell, JE, Watling, RM, Ashby, D & Smyth, RL. Oral protein energy supplements for children with cystic fibrosis: CALICO multicentre randomised controlled trial. *Bmj* 332, 632-636 (2006).
14. Francis, DK, Smith, J, Saljuqi, T & Watling, RM. Oral protein calorie supplementation for children with chronic disease. *Cochrane Database Syst Rev*, Cd001914 (2015).
15. Smyth, RL & Walters, S. Oral calorie supplements for cystic fibrosis. *Cochrane Database Syst Rev* 10, Cd000406 (2012).
16. Kalnins, D, Corey, M, Ellis, L, Pencharz, PB, Tullis, E & Durie, PR. Failure of conventional strategies to improve nutritional status in malnourished adolescents and adults with cystic fibrosis. *J Pediatr* 147, 399-401 (2005).
17. Haack, A & Garbi-Novaes, MR. Cystic fibrosis patients assisted by a program nutrition therapy: assessment of the use of supplements in patients colonized and non colonized by *P. aeruginosa*. *Rev Invest Clin* 66, 136-143 (2014).
18. White, H, Morton, AM, Peckham, DG & Conway, SP. Dietary intakes in adult patients with cystic fibrosis--do they achieve guidelines? *J Cyst Fibros* 3, 1-7 (2004).
19. Hollander, FM, van Pierre, DD, de Roos, NM, van de Graaf, EA & Iestra, JA. Effects of nutritional status and dietetic interventions on survival in Cystic Fibrosis patients before and after lung transplantation. *J Cyst Fibros* 13, 212-218 (2014).
20. Best, C, Brearley, A, Gaillard, P, Regelman, W, Billings, J, Dunitz, J, *et al.* A pre-post retrospective study of patients with cystic fibrosis and gastrostomy tubes. *J Pediatr Gastroenterol Nutr* 53, 453-458 (2011).
21. Efrati, O, Mei-Zahav, M, Rivlin, J, Kerem, E, Blau, H, Barak, A, *et al.* Long term nutritional rehabilitation by gastrostomy in Israeli patients with cystic fibrosis: clinical outcome in advanced pulmonary disease. *J Pediatr Gastroenterol Nutr* 42, 222-228 (2006).
22. White, H, Morton, AM, Conway, SP & Peckham, DG. Enteral tube feeding in adults with cystic fibrosis; patient choice and impact on long term outcomes. *J Cyst Fibros* 12, 616-622 (2013).
23. Bradley, GM, Carson, KA, Leonard, AR, Mogayzel, PJ, Jr. & Oliva-Hemker, M. Nutritional outcomes following gastrostomy in children with cystic fibrosis. *Pediatr Pulmonol* 47, 743-748 (2012).
24. Truby, H, Cowlshaw, P, O'Neil, C & Wainwright, C. The long term efficacy of gastrostomy feeding in children with cystic fibrosis on anthropometric markers of nutritional status and pulmonary function. *Open Respir Med J* 3, 112-115 (2009).
25. Van Biervliet, S, De Waele, K, Van Winkel, M & Robberecht, E. Percutaneous endoscopic gastrostomy in cystic fibrosis: patient acceptance and effect of overnight tube feeding on nutritional status. *Acta Gastroenterol Belg* 67, 241-244 (2004).
26. Vandeleur, M, Massie, J & Oliver, M. Gastrostomy in children with cystic fibrosis and portal hypertension. *J Pediatr Gastroenterol Nutr* 57, 245-247 (2013).

27. Oliver, MR, Heine, RG, Ng, CH, Volders, E & Olinsky, A. Factors affecting clinical outcome in gastrostomy-fed children with cystic fibrosis. *Pediatr Pulmonol* 37, 324-329 (2004).
28. Woestenenk, JW, Castelijns, SJ, van der Ent, CK & Houwen, RH. Nutritional intervention in patients with Cystic Fibrosis: a systematic review. *J Cyst Fibros* 12, 102-115 (2013).
29. White, H, Pollard, K, Etherington, C, Clifton, I, Morton, AM, Owen, D, *et al.* Nutritional decline in cystic fibrosis related diabetes: the effect of intensive nutritional intervention. *J Cyst Fibros* 8, 179-185 (2009).
30. Allen, JR, McCauley, JC, Selby, AM, Waters, DL, Gruca, MA, Baur, LA, *et al.* Differences in resting energy expenditure between male and female children with cystic fibrosis. *J Pediatr* 142, 15-19 (2003).
31. Barclay, A, Allen, JR, Blyler, E, Yap, J, Gruca, MA, Asperen, PV, *et al.* Resting energy expenditure in females with cystic fibrosis: is it affected by puberty? *Eur J Clin Nutr* 61, 1207-1212 (2007).
32. Beghin, L, Gottrand, F, Michaud, L, Loeuille, GA, Wizla-Derambure, N, Sardet, A, *et al.* Impact of intravenous antibiotic therapy on total daily energy expenditure and physical activity in cystic fibrosis children with *Pseudomonas aeruginosa* pulmonary exacerbation. *Pediatr Res* 54, 756-761 (2003).
33. Bines, JE, Truby, HD, Armstrong, DS, Phelan, PD & Grimwood, K. Energy metabolism in infants with cystic fibrosis. *J Pediatr* 140, 527-533 (2002).
34. Castro, M, Diamanti, A, Gambarara, M, Bella, S, Lucidi, V, Papadatou, B, *et al.* Resting energy expenditure in young patients with cystic fibrosis receiving antibiotic therapy for acute respiratory exacerbations. *Clin Nutr* 21, 141-144 (2002).
35. Davies, PS, Erskine, JM, Hambidge, KM & Accurso, FJ. Longitudinal investigation of energy expenditure in infants with cystic fibrosis. *Eur J Clin Nutr* 56, 940-946 (2002).
36. Dorlochter, L, Helgheim, V, Roksund, OD, Rosendahl, K & Fluge, G. Shwachman-Kulczycki score and resting energy expenditure in cystic fibrosis. *J Cyst Fibros* 2, 148-151 (2003).
37. Johnson, MR, Ferkol, TW & Shepherd, RW. Energy cost of activity and exercise in children and adolescents with cystic fibrosis. *J Cyst Fibros* 5, 53-58 (2006).
38. Magoffin, A, Allen, JR, McCauley, J, Gruca, MA, Peat, J, Van Asperen, P, *et al.* Longitudinal analysis of resting energy expenditure in patients with cystic fibrosis. *J Pediatr* 152, 703-708 (2008).
39. Marin, VB, Velandia, S, Hunter, B, Gattas, V, Fielbaum, O, Herrera, O, *et al.* Energy expenditure, nutrition status, and body composition in children with cystic fibrosis. *Nutrition* 20, 181-186 (2004).
40. Mc Closkey, M, Redmond, AO, Mc Cabe, C, Pyper, S, Westerterp, KR & Elborn, SJ. Energy balance in cystic fibrosis when stable and during a respiratory exacerbation. *Clin Nutr* 23, 1405-1412 (2004).
41. Moudiou, T, Galli-Tsinopoulou, A, Vamvakoudis, E & Nousia-Arvanitakis, S. Resting energy expenditure in cystic fibrosis as an indicator of disease severity. *J Cyst Fibros* 6, 131-136 (2007).
42. Stallings, VA, Tomezsko, JL, Schall, JI, Mascarenhas, MR, Stettler, N, Scanlin, TF, *et al.* Adolescent development and energy expenditure in females with cystic fibrosis. *Clin Nutr* 24, 737-745 (2005).
43. National Health and Medical Research Council. Nutrient Reference Values for Australia and New Zealand. (National Health and Medical Research Council of Australia and Ministry of Health New Zealand, Australia, 2006). [http://www.nhmrc.gov.au/files\\_nhmrc/publications/attachments/n35.pdf](http://www.nhmrc.gov.au/files_nhmrc/publications/attachments/n35.pdf)
44. De Vizia, B, Raia, V, Spano, C, Pavlidis, C, Coruzzo, A & Alessio, M. Effect of an 8-month treatment with omega-3 fatty acids (eicosapentaenoic and docosahexaenoic) in patients with cystic fibrosis. *JPEN J Parenter Enteral Nutr* 27, 52-57 (2003).
45. Jumpsen, JA, Brown, NE, Thomson, AB, Paul Man, SF, Goh, YK, Ma, D, *et al.* Fatty acids in blood and intestine following docosahexaenoic acid supplementation in adults with cystic fibrosis. *J Cyst Fibros* 5, 77-84 (2006).
46. Oliver, C & Watson, H. Omega-3 fatty acids for cystic fibrosis. *Cochrane Database Syst Rev* 1, Cd002201 (2016).
47. Bines, JE, Truby, HD, Armstrong, DS, Carzino, R & Grimwood, K. Vitamin A and E deficiency and lung disease in infants with cystic fibrosis. *J Paediatr Child Health* 41, 663-668 (2005).
48. Wood, LG, Fitzgerald, DA, Lee, AK & Garg, ML. Improved antioxidant and fatty acid status of patients with cystic fibrosis after antioxidant supplementation is linked to improved lung function. *Am J Clin Nutr* 77, 150-159 (2003).
49. Dorlochter, L, Aksnes, L & Fluge, G. Faecal elastase-1 and fat-soluble vitamin profiles in patients with cystic fibrosis in Western Norway. *Eur J Nutr* 41, 148-152 (2002).
50. Lezo, A, Biasi, F, Massarenti, P, Calabrese, R, Poli, G, Santini, B, *et al.* Oxidative stress in stable cystic fibrosis patients: do we need higher antioxidant plasma levels? *J Cyst Fibros* 12, 35-41 (2013).
51. Rana, M, Wong-See, D, Katz, T, Gaskin, K, Whitehead, B, Jaffe, A, *et al.* Fat-soluble vitamin deficiency in children and adolescents with cystic fibrosis. *J Clin Pathol* 67, 605-608 (2014).
52. Hakim, F, Kerem, E, Rivlin, J, Bentur, L, Stankiewicz, H, Bdolach-Abram, T, *et al.* Vitamins A and E and pulmonary exacerbations in patients with cystic fibrosis. *J Pediatr Gastroenterol Nutr* 45, 347-353 (2007).
53. Siwamogsatham, O, Dong, W, Binongo, JN, Chowdhury, R, Alvarez, JA, Feinman, SJ, *et al.* Relationship Between Fat-Soluble Vitamin Supplementation and Blood Concentrations in Adolescent and Adult Patients With Cystic Fibrosis. *Nutr Clin Pract* 29, 491-497 (2014).



54. Oudshoorn, JH, Klijn, PH, Hofman, Z, Voorbij, HA, van der Ent, CK, Berger, R, *et al.* Dietary supplementation with multiple micronutrients: no beneficial effects in pediatric cystic fibrosis patients. *J Cyst Fibros* 6, 35-40 (2007).
55. Brei, C, Simon, A, Krawinkel, MB & Naehrlich, L. Individualized vitamin A supplementation for patients with cystic fibrosis. *Clin Nutr* 32, 805-810 (2013).
56. Graham-Maar, RC, Schall, JI, Stettler, N, Zemel, BS & Stallings, VA. Elevated vitamin A intake and serum retinol in preadolescent children with cystic fibrosis. *Am J Clin Nutr* 84, 174-182 (2006).
57. Maqbool, A, Graham-Maar, RC, Schall, JI, Zemel, BS & Stallings, VA. Vitamin A intake and elevated serum retinol levels in children and young adults with cystic fibrosis. *J Cyst Fibros* 7, 137-141 (2008).
58. Rivas-Crespo, MF, Gonzalez Jimenez, D, Acuna Quiros, MD, Sojo Aguirre, A, Heredia Gonzalez, S, Diaz Martin, JJ, *et al.* High serum retinol and lung function in young patients with cystic fibrosis. *J Pediatr Gastroenterol Nutr* 56, 657-662 (2013).
59. Whatham, A, Suttle, C, Blumenthal, C, Allen, J & Gaskin, K. ERGs in children with pancreatic enzyme insufficient and pancreatic enzyme sufficient cystic fibrosis. *Doc Ophthalmol* 119, 43-50 (2009).
60. Greer, RM, Buntain, HM, Lewindon, PJ, Wainwright, CE, Potter, JM, Wong, JC, *et al.* Vitamin A levels in patients with CF are influenced by the inflammatory response. *J Cyst Fibros* 3, 143-149 (2004).
61. Woestenenk, JW, Broos, N, Stellato, RK, Arets, HG, van der Ent, CK & Houwen, RH. Vitamin A intake and serum retinol levels in children and adolescents with cystic fibrosis. *Clin Nutr* 35, 654-659 (2016).
62. Grossmann, RE, Zughaier, SM, Liu, S, Lyles, RH & Tangpricha, V. Impact of vitamin D supplementation on markers of inflammation in adults with cystic fibrosis hospitalized for a pulmonary exacerbation. *Eur J Clin Nutr* 66, 1072-1074 (2012).
63. Grossmann, RE, Zughaier, SM, Kumari, M, Seydafkan, S, Lyles, RH, Liu, S, *et al.* Pilot study of vitamin D supplementation in adults with cystic fibrosis pulmonary exacerbation: A randomized, controlled trial. *Dermatoendocrinol* 4, 191-197 (2012).
64. Sexauer, WP, Hadeh, A, Ohman-Strickland, PA, Zanni, RL, Varlotta, L, Holsclaw, D, *et al.* Vitamin D deficiency is associated with pulmonary dysfunction in cystic fibrosis. *J Cyst Fibros* 14, 497-506 (2015).
65. Simoneau, T, Bazzaz, O, Sawicki, GS & Gordon, C. Vitamin D status in children with cystic fibrosis. Associations with inflammation and bacterial colonization. *Ann Am Thorac Soc* 11, 205-210 (2014).
66. Vanstone, MB, Egan, ME, Zhang, JH & Carpenter, TO. Association between serum 25-hydroxyvitamin D level and pulmonary exacerbations in cystic fibrosis. *Pediatr Pulmonol* 50, 441-446 (2015).
67. McCauley, LA, Thomas, W, Laguna, TA, Regelmann, WE, Moran, A & Polgreen, LE. Vitamin D deficiency is associated with pulmonary exacerbations in children with cystic fibrosis. *Ann Am Thorac Soc* 11, 198-204 (2014).
68. Pincikova, T, Nilsson, K, Moen, IE, Karpati, F, Fluge, G, Hollsing, A, *et al.* Inverse relation between vitamin D and serum total immunoglobulin G in the Scandinavian Cystic Fibrosis Nutritional Study. *Eur J Clin Nutr* 65, 102-109 (2011).
69. Nowson, CA, McGrath, JJ, Ebeling, PR, Haikerwal, A, Daly, RM, Sanders, KM, *et al.* Vitamin D and health in adults in Australia and New Zealand: a position statement. *Med J Aust* 196, 686-687 (2012).
70. Robberecht, E, Vandewalle, S, Wehlou, C, Kaufman, JM & De Schepper, J. Sunlight is an important determinant of vitamin D serum concentrations in cystic fibrosis. *Eur J Clin Nutr* 65, 574-579 (2011).
71. Neville, LA & Ranganathan, SC. Vitamin D in infants with cystic fibrosis diagnosed by newborn screening. *J Paediatr Child Health* 45, 36-41 (2009).
72. Lansing, AH, McDonald, C, Patel, RA, Meihls, S, Crowell, K, Chatfield, B, *et al.* Vitamin D deficiency in pediatric patients with cystic fibrosis: associated risk factors in the northern United States. *South Med J* 108, 164-169 (2015).
73. Ahmaren, D, Pentony, M, Healy, F & Zaid, A. A one-year retrospective review of vitamin D level, bone profile, liver function tests and body mass index in children with cystic fibrosis in a children's university hospital. *Int J Disabil Hum Dev* 14, 31-36 (2015).
74. Chavasse, RJ, Francis, J, Balfour-Lynn, I, Rosenthal, M & Bush, A. Serum vitamin D levels in children with cystic fibrosis. *Pediatr Pulmonol* 38, 119-122 (2004).
75. Stephenson, A, Brotherwood, M, Robert, R, Atenafu, E, Corey, M & Tullis, E. Cholecalciferol significantly increases 25-hydroxyvitamin D concentrations in adults with cystic fibrosis. *Am J Clin Nutr* 85, 1307-1311 (2007).
76. Norton, L, Page, S, Sheehan, M, Mazurak, V, Brunet-Wood, K & Larsen, B. Prevalence of inadequate vitamin d status and associated factors in children with cystic fibrosis. *Nutr Clin Pract* 30, 111-116 (2015).
77. Tangpricha, V, Kelly, A, Stephenson, A, Maguiness, K, Enders, J, Robinson, KA, *et al.* An update on the screening, diagnosis, management, and treatment of vitamin D deficiency in individuals with cystic fibrosis: evidence-based recommendations from the Cystic Fibrosis Foundation. *J Clin Endocrinol Metab* 97, 1082-1093 (2012).
78. Turck, D, Braegger, CP, Colombo, C, Declercq, D, Morton, A, Pancheva, R, *et al.* ESPEN-ESPGHAN-ECFS guidelines on nutrition care for infants, children, and adults with cystic fibrosis. *Clin Nutr* 35, 557-577 (2016).
79. Shepherd, D, Belessis, Y, Katz, T, Morton, J, Field, P & Jaffe, A. Single high-dose oral vitamin D3 (stoss) therapy--a solution to vitamin D deficiency in children with cystic fibrosis? *J Cyst Fibros* 12, 177-182 (2013).
80. Khazai, NB, Judd, SE, Jeng, L, Wolfenden, LL, Stecenko, A, Ziegler, TR, *et al.* Treatment and prevention of vitamin D insufficiency in cystic fibrosis patients: comparative efficacy of ergocalciferol, cholecalciferol, and UV light. *J Clin Endocrinol Metab* 94, 2037-2043 (2009).

81. Hollander, FM, de Roos, NM, Dopheide, J, Hoekstra, T & van Berkhout, FT. Self-reported use of vitamins and other nutritional supplements in adult patients with cystic fibrosis. Is daily practice in concordance with recommendations? *Int J Vitam Nutr Res* 80, 408-415 (2010).
82. Huang, SH, Schall, JI, Zemel, BS & Stallings, VA. Vitamin E status in children with cystic fibrosis and pancreatic insufficiency. *J Pediatr* 148, 556-559 (2006).
83. Kosciak, RL, Farrell, PM, Kosorok, MR, Zaremba, KM, Laxova, A, Lai, HC, *et al.* Cognitive function of children with cystic fibrosis: deleterious effect of early malnutrition. *Pediatrics* 113, 1549-1558 (2004).
84. Kosciak, RL, Lai, HJ, Laxova, A, Zaremba, KM, Kosorok, MR, Douglas, JA, *et al.* Preventing early, prolonged vitamin E deficiency: an opportunity for better cognitive outcomes via early diagnosis through neonatal screening. *J Pediatr* 147, S51-56 (2005).
85. Sagel, SD, Sontag, MK, Anthony, MM, Emmett, P & Papas, KA. Effect of an antioxidant-rich multivitamin supplement in cystic fibrosis. *J Cyst Fibros* 10, 31-36 (2011).
86. Woestenenk, JW, Broos, N, Stellato, RK, Arets, HG, van der Ent, CK & Houwen, RH. Vitamin E intake, alpha-tocopherol levels and pulmonary function in children and adolescents with cystic fibrosis. *Br J Nutr* 113, 1096-1101 (2015).
87. Borowitz, D, Robinson, KA, Rosenfeld, M, Davis, SD, Sabadosa, KA, Spear, SL, *et al.* Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis. *J Pediatr* 155, S73-93 (2009).
88. Dougherty, KA, Schall, JI & Stallings, VA. Suboptimal vitamin K status despite supplementation in children and young adults with cystic fibrosis. *Am J Clin Nutr* 92, 660-667 (2010).
89. Mosler, K, von Kries, R, Vermeer, C, Saupe, J, Schmitz, T & Schuster, A. Assessment of vitamin K deficiency in CF--how much sophistication is useful? *J Cyst Fibros* 2, 91-96 (2003).
90. van Hoorn, JH, Hendriks, JJ, Vermeer, C & Forget, PP. Vitamin K supplementation in cystic fibrosis. *Arch Dis Child* 88, 974-975 (2003).
91. Drury, D, Grey, VL, Ferland, G, Gundberg, C & Lands, LC. Efficacy of high dose phylloquinone in correcting vitamin K deficiency in cystic fibrosis. *J Cyst Fibros* 7, 457-459 (2008).
92. Conway, SP, Wolfe, SP, Brownlee, KG, White, H, Oldroyd, B, Truscott, JG, *et al.* Vitamin K status among children with cystic fibrosis and its relationship to bone mineral density and bone turnover. *Pediatrics* 115, 1325-1331 (2005).
93. Fewtrell, MS, Benden, C, Williams, JE, Chomtho, S, Ginty, F, Nigdikar, SV, *et al.* Undercarboxylated osteocalcin and bone mass in 8-12 year old children with cystic fibrosis. *J Cyst Fibros* 7, 307-312 (2008).
94. Nicolaidou, P, Stavrinadis, I, Loukou, I, Papadopoulou, A, Georgouli, H, Douros, K, *et al.* The effect of vitamin K supplementation on biochemical markers of bone formation in children and adolescents with cystic fibrosis. *Eur J Pediatr* 165, 540-545 (2006).
95. Grey, V, Atkinson, S, Drury, D, Casey, L, Ferland, G, Gundberg, C, *et al.* Prevalence of low bone mass and deficiencies of vitamins D and K in pediatric patients with cystic fibrosis from 3 Canadian centers. *Pediatrics* 122, 1014-1020 (2008).
96. Keevil, B, Rowlands, D, Burton, I & Webb, AK. Assessment of iron status in cystic fibrosis patients. *Ann Clin Biochem* 37 ( Pt 5), 662-665 (2000).
97. Khalid, S, McGrowder, D, Kemp, M & Johnson, P. The use of soluble transferrin receptor to assess iron deficiency in adults with cystic fibrosis. *Clin Chim Acta* 378, 194-200 (2007).
98. Gifford, AH, Alexandru, DM, Li, Z, Dorman, DB, Moulton, LA, Price, KE, *et al.* Iron supplementation does not worsen respiratory health or alter the sputum microbiome in cystic fibrosis. *J Cyst Fibros* 13, 311-318 (2014).
99. Gontijo-Amaral, C, Guimaraes, EV & Camargos, P. Oral magnesium supplementation in children with cystic fibrosis improves clinical and functional variables: a double-blind, randomized, placebo-controlled crossover trial. *Am J Clin Nutr* 96, 50-56 (2012).
100. Kriemler, S, Wilk, B, Schurer, W, Wilson, WM & Bar-Or, O. Preventing dehydration in children with cystic fibrosis who exercise in the heat. *Med Sci Sports Exerc* 31, 774-779 (1999).
101. Brown, MB, McCarty, NA & Millard-Stafford, M. High-sweat Na<sup>+</sup> in cystic fibrosis and healthy individuals does not diminish thirst during exercise in the heat. *Am J Physiol Regul Integr Comp Physiol* 301, R1177-1185 (2011).
102. Guimaraes, EV, Schettino, GC, Camargos, PA & Penna, FJ. Prevalence of hyponatremia at diagnosis and factors associated with the longitudinal variation in serum sodium levels in infants with cystic fibrosis. *J Pediatr* 161, 285-289 (2012).
103. Akanli, L, Lowenthal, DB, Gjonaj, S & Dozor, AJ. Plasma and red blood cell zinc in cystic fibrosis. *Pediatr Pulmonol* 35, 2-7 (2003).
104. Sharma, G, Lodha, R, Shastri, S, Saini, S, Kapil, A, Singla, M, *et al.* Zinc Supplementation for One Year Among Children with Cystic Fibrosis Does Not Decrease Pulmonary Infection. *Respir Care* 61, 78-84 (2016).
105. Abdulhamid, I, Beck, FW, Millard, S, Chen, X & Prasad, A. Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. *Pediatr Pulmonol* 43, 281-287 (2008).
106. Van Biervliet, S, Vande Velde, S, Van Biervliet, JP & Robberecht, E. The effect of zinc supplements in cystic fibrosis patients. *Ann Nutr Metab* 52, 152-156 (2008).
107. Atae, P, Najafi, M, Gharagozlou, M, Aflatounian, M, Mahmoudi, M, Khodadad, A, *et al.* Effect of supplementary zinc on body mass index, pulmonary function and hospitalization in children with cystic fibrosis. *Turk J Pediatr* 56, 127-132 (2014).
108. Dampousse, V, Mailhot, M, Berthiaume, Y, Rabasa-Lhoret, R & Mailhot, G. Plasma zinc in adults with cystic fibrosis: correlations with clinical outcomes. *J Trace Elem Med Biol* 28, 60-64 (2014).





109. Maqbool, A, Schall, JI, Zemel, BS, Garcia-Espana, JF & Stallings, VA. Plasma zinc and growth status in preadolescent children with cystic fibrosis. *J Pediatr Gastroenterol Nutr* 43, 95-101 (2006).
110. Van Biervliet, S, Van Biervliet, JP, Vande Velde, S & Robberecht, E. Serum zinc concentrations in cystic fibrosis patients aged above 4 years: a cross-sectional evaluation. *Biol Trace Elem Res* 119, 19-26 (2007).
111. Symonds, EL, Omari, TI, Webster, JM, Davidson, GP & Butler, RN. Relation between pancreatic lipase activity and gastric emptying rate in children with cystic fibrosis. *J Pediatr* 143, 772-775 (2003).
112. van der Haak, N, Boase, J, Davidson, G, Butler, R, Miller, M, Kaambwa, B, *et al.* Preliminary report of the (13)C-mixed triglyceride breath test to assess timing of pancreatic enzyme replacement therapy in children with cystic fibrosis. *J Cyst Fibros* 15, 669-674 (2016).
113. Littlewood, JM, Connett, GJ, Sander-Struckmeier, S & Henniges, F. A 2-year post-authorization safety study of high-strength pancreatic enzyme replacement therapy (pancreatin 40,000) in cystic fibrosis. *Expert Opinion on Drug Safety* 10, 197-203 (2011).
114. Trapnell, BC, Maguiness, K, Graff, GR, Boyd, D, Beckmann, K & Caras, S. Efficacy and safety of Creon 24,000 in subjects with exocrine pancreatic insufficiency due to cystic fibrosis. *Journal of Cystic Fibrosis* 8, 370-377 (2009).
115. Konstan, MW, Liou, TG, Strausbaugh, SD, Ahrens, R, Kanga, JF, Graff, GR, *et al.* Efficacy and safety of a new formulation of pancrelipase (Ultrase MT20) in the treatment of malabsorption in exocrine pancreatic insufficiency in cystic fibrosis. *Gastroenterology Research and Practice* (2010).
116. Kashirskaya, NY, Kapranov, NI, Sander-Struckmeier, S & Kovalev, V. Safety and efficacy of Creon Micro in children with exocrine pancreatic insufficiency due to cystic fibrosis. *Journal of Cystic Fibrosis* 14, 275-281 (2015).
117. Borowitz, D, Goss, CH, Stevens, C, Hayes, D, Newman, L, O'Rourke, A, *et al.* Safety and preliminary clinical activity of a novel pancreatic enzyme preparation in pancreatic insufficient cystic fibrosis patients. *Pancreas* 32, 258-263 (2006).
118. Graff, GR, McNamara, J, Royall, J, Caras, S & Forssmann, K. Safety and tolerability of a new formulation of pancrelipase delayed-release capsules (CREON) in children under seven years of age with exocrine pancreatic insufficiency due to cystic fibrosis: An open-label, multicentre, single-treatment-arm study. *Clinical Drug Investigation* 30, 351-364 (2010).
119. Borowitz, D, Goss, CH, Limauro, S, Konstan, MW, Blake, K, Casey, S, *et al.* Study of a novel pancreatic enzyme replacement therapy in pancreatic insufficient subjects with cystic fibrosis. *J Pediatr* 149, 658-662 (2006).
120. Van De Vijver, E, Desager, K, Mulberg, AE, Staelens, S, Verkade, HJ, Bodewes, FA, *et al.* Treatment of infants and toddlers with cystic fibrosis-related pancreatic insufficiency and fat malabsorption with pancrelipase MT. *Journal of Pediatric Gastroenterology and Nutrition* 53, 61-64 (2011).
121. Konstan, MW, Stern, RC, Trout, JR, Sherman, JM, Eigen, H, Wagener, JS, *et al.* Ultrase MT12 and ultrase MT20 in the treatment of exocrine pancreatic insufficiency in cystic fibrosis: Safety and efficacy. *Alimentary Pharmacology and Therapeutics* 20, 1365-1371 (2004).
122. Trapnell, BC, Strausbaugh, SD, Woo, MS, Tong, SY, Silber, SA, Mulberg, AE, *et al.* Efficacy and safety of PANCREAZE for treatment of exocrine pancreatic insufficiency due to cystic fibrosis. *Journal of Cystic Fibrosis* 10, 350-356 (2011).
123. Graff, GR, Maguiness, K, McNamara, J, Morton, R, Boyd, D, Beckmann, K, *et al.* Efficacy and tolerability of a new formulation of pancrelipase delayed-release capsules in children aged 7 to 11 years with exocrine pancreatic insufficiency and cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled, two-period crossover, superiority study. *Clinical Therapeutics* 32, 89-103 (2010).
124. Wooldridge, JL, Heubi, JE, Amaro-Galvez, R, Boas, SR, Blake, KV, Nasr, SZ, *et al.* EUR-1008 pancreatic enzyme replacement is safe and effective in patients with cystic fibrosis and pancreatic insufficiency. *Journal of Cystic Fibrosis* 8, 405-417 (2009).
125. Borowitz, D, Stevens, C, Brettman, LR, Campion, M, Wilschanski, M, Thompson, H, *et al.* Liprotamase long-term safety and support of nutritional status in pancreatic-insufficient cystic fibrosis. *J Pediatr Gastroenterol Nutr* 54, 248-257 (2012).
126. Wooldridge, JL, Schaeffer, D, Jacobs, D & Thieroff-Ekerdt, R. Long-term experience with ZENPEP in infants with exocrine pancreatic insufficiency associated with cystic fibrosis. *Journal of Pediatric Gastroenterology and Nutrition* 59, 612-615 (2014).
127. Munck, A, Duhamel, JF, Lamireau, T, Le Luyer, B, Le Tallec, C, Bellon, G, *et al.* Pancreatic enzyme replacement therapy for young cystic fibrosis patients. *Journal of Cystic Fibrosis* 8, 14-18 (2009).
128. Konstan, MW, Accurso, FJ, Nasr, SZ, Ahrens, RC & Graff, GR. Efficacy and safety of a unique enteric-coated bicarbonate-buffered pancreatic enzyme replacement therapy in children and adults with cystic fibrosis. *Clinical Investigation* 3, 723-729 (2013).
129. Brady, MS, Garson, JL, Krug, SK, Kaul, A, Rickard, KA, Caffrey, HH, *et al.* An enteric-coated high-buffered pancrelipase reduces steatorrhea in patients with cystic fibrosis: a prospective, randomized study. *J Am Diet Assoc* 106, 1181-1186 (2006).
130. Baker, SS, Borowitz, D, Duffy, L, Fitzpatrick, L, Gyamfi, J & Baker, RD. Pancreatic enzyme therapy and clinical outcomes in patients with cystic fibrosis. *J Pediatr* 146, 189-193 (2005).
131. Haupt, M, Wang, D, Kim, S, Schechter, MS & McColley, SA. Analysis of pancreatic enzyme replacement therapy dosing on nutritional outcomes in children with cystic fibrosis. *Pediatric Pulmonology* 46, 395 (2011).
132. Stallings, VA, Stark, LJ, Robinson, KA, Feranchak, AP & Quinton, H. Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: results of a systematic review. *J Am Diet Assoc* 108, 832-839 (2008).
133. Proesmans, M & De Boeck, K. Omeprazole, a proton pump inhibitor, improves residual steatorrhea in cystic fibrosis patients treated with high dose pancreatic enzymes. *Eur J Pediatr* 162, 760-763 (2003).

134. Francisco, MP, Wagner, MH, Sherman, JM, Theriaque, D, Bowser, E & Novak, DA. Ranitidine and omeprazole as adjuvant therapy to pancrelipase to improve fat absorption in patients with cystic fibrosis. *Journal of Pediatric Gastroenterology and Nutrition* 35, 79-83 (2002).
135. Ng, SM & Franchini, AJ. Drug therapies for reducing gastric acidity in people with cystic fibrosis. *Cochrane Database Syst Rev* 7, CD003424 (2014).
136. Sheikh, SI, Ryan-Wenger, NA & McCoy, KS. Outcomes of surgical management of severe GERD in patients with cystic fibrosis. *Pediatr Pulmonol* 48, 556-562 (2013).
137. Boesch, RP & Acton, JD. Outcomes of fundoplication in children with cystic fibrosis. *J Pediatr Surg* 42, 1341-1344 (2007).
138. Sabati, AA, Kempainen, RR, Milla, CE, Ireland, M, Schwarzenberg, SJ, Dunitz, JM, *et al.* Characteristics of gastroesophageal reflux in adults with cystic fibrosis. *J Cyst Fibros* 9, 365-370 (2010).
139. Dimango, E, Walker, P, Keating, C, Berdella, M, Robinson, N, Langfelder-Schwind, E, *et al.* Effect of esomeprazole versus placebo on pulmonary exacerbations in cystic fibrosis. *BMC Pulm Med* 14, 21 (2014).
140. Declercq, D, Van Biervliet, S & Robberecht, E. Nutrition and pancreatic enzyme intake in patients with cystic fibrosis with distal intestinal obstruction syndrome. *Nutr Clin Pract* 30, 134-137 (2015).
141. Munck, A, Alberti, C, Colombo, C, Kashirskaya, N, Ellemunter, H, Fotoulaki, M, *et al.* International prospective study of distal intestinal obstruction syndrome in cystic fibrosis: Associated factors and outcome. *J Cyst Fibros* (2016).
142. Proesmans, M & De Boeck, K. Evaluation of dietary fiber intake in Belgian children with cystic fibrosis: is there a link with gastrointestinal complaints? *J Pediatr Gastroenterol Nutr* 35, 610-614 (2002).
143. van der Doef, HP, Kokke, FT, Beek, FJ, Woestenenk, JW, Froeling, SP & Houwen, RH. Constipation in pediatric cystic fibrosis patients: an underestimated medical condition. *J Cyst Fibros* 9, 59-63 (2010).
144. Debray, D, Kelly, D, Houwen, R, Strandvik, B & Colombo, C. Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease. *J Cyst Fibros* 10 Suppl 2, S29-36 (2011).
145. American Diabetes Association. Standards of Medical Care in Diabetes 2015. *The Journal of Clinical and Applied Research and Education* 38(2015).
146. American Diabetes Association. Standards of Medical Care in Diabetes 2016. *The Journal of Clinical and Applied Research and Education* 39(2016).
147. O'Riordan, SM, Hindmarsh, P, Hill, NR, Matthews, DR, George, S, Greally, P, *et al.* Validation of continuous glucose monitoring in children and adolescents with cystic fibrosis: a prospective cohort study. *Diabetes Care* 32, 1020-1022 (2009).
148. Moreau, F, Weiller, MA, Rosner, V, Weiss, L, Hasselmann, M, Pinget, M, *et al.* Continuous glucose monitoring in cystic fibrosis patients according to the glucose tolerance. *Horm Metab Res* 40, 502-506 (2008).
149. Sermet-Gaudelus, I, Bianchi, ML, Garabedian, M, Aris, RM, Morton, A, Hardin, DS, *et al.* European cystic fibrosis bone mineralisation guidelines. *J Cyst Fibros* 10 Suppl 2, S16-23 (2011).
150. Haworth, CS, Jones, AM, Adams, JE, Selby, PL & Webb, AK. Randomised double blind placebo controlled trial investigating the effect of calcium and vitamin D supplementation on bone mineral density and bone metabolism in adult patients with cystic fibrosis. *J Cyst Fibros* 3, 233-236 (2004).
151. Hillman, LS, Cassidy, JT, Popescu, MF, Hewett, JE, Kyger, J & Robertson, JD. Percent true calcium absorption, mineral metabolism, and bone mineralization in children with cystic fibrosis: effect of supplementation with vitamin D and calcium. *Pediatr Pulmonol* 43, 772-780 (2008).
152. Australian Government Department of Health. National Antenatal Care Guidelines. (ed. Health, D.o.) (Australian Government, Australia, 2012). <http://www.health.gov.au/antenatal>
153. New Zealand Ministry of Health. Folic Acid, Iodine, Vitamin D. (New Zealand Government Ministry of Health, Wellington New Zealand, 2016). <http://www.health.govt.nz/your-health/pregnancy-and-kids/pregnancy/helpful-advice-during-pregnancy/folic-acid-iodine-and-vitamin-d>
154. Ramsey, BW, Davies, J, McElvaney, NG, Tullis, E, Bell, SC, Drevinek, P, *et al.* A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. *N Engl J Med* 365, 1663-1672 (2011).
155. Davies, JC, Wainwright, CE, Canny, GJ, Chilvers, MA, Howenstine, MS, Munck, A, *et al.* Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. *Am J Respir Crit Care Med* 187, 1219-1225 (2013).
156. Barry, PJ, Plant, BJ, Nair, A, Bicknell, S, Simmonds, NJ, Bell, NJ, *et al.* Effects of ivacaftor in patients with cystic fibrosis who carry the G551D mutation and have severe lung disease. *Chest* 146, 152-158 (2014).
157. De Boeck, K, Munck, A, Walker, S, Faro, A, Hiatt, P, Gilmartin, G, *et al.* Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation. *J Cyst Fibros* 13, 674-680 (2014).
158. McKone, EF, Borowitz, D, Drevinek, P, Griese, M, Konstan, MW, Wainwright, C, *et al.* Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST). *Lancet Respir Med* 2, 902-910 (2014).
159. Rowe, SM, Heltshe, SL, Gonska, T, Donaldson, SH, Borowitz, D, Gelfond, D, *et al.* Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis. *Am J Respir Crit Care Med* 190, 175-184 (2014).



160. Sawicki, GS, McKone, EF, Pasta, DJ, Millar, SJ, Wagener, JS, Johnson, CA, *et al.* Sustained Benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data. *Am J Respir Crit Care Med* 192, 836-842 (2015).
161. Taylor-Cousar, J, Niknian, M, Gilmartin, G & Pilewski, JM. Effect of ivacaftor in patients with advanced cystic fibrosis and a G551D-CFTR mutation: Safety and efficacy in an expanded access program in the United States. *J Cyst Fibros* 15, 116-122 (2016).
162. Flume, PA, Liou, TG, Borowitz, DS, Li, H, Yen, K, Ordonez, CL, *et al.* Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. *Chest* 142, 718-724 (2012).
163. Bellin, MD, Laguna, T, Leschyshyn, J, Regelman, W, Dunitz, J, Billings, J, *et al.* Insulin secretion improves in cystic fibrosis following ivacaftor correction of CFTR: a small pilot study. *Pediatr Diabetes* 14, 417-421 (2013).
164. Bruzzese, E, Callegari, ML, Raia, V, Viscovo, S, Scotto, R, Ferrari, S, *et al.* Disrupted intestinal microbiota and intestinal inflammation in children with cystic fibrosis and its restoration with Lactobacillus GG: a randomised clinical trial. *PLoS One* 9, e87796 (2014).
165. Bruzzese, E, Raia, V, Spagnuolo, MI, Volpicelli, M, De Marco, G, Maiuri, L, *et al.* Effect of Lactobacillus GG supplementation on pulmonary exacerbations in patients with cystic fibrosis: a pilot study. *Clin Nutr* 26, 322-328 (2007).
166. Bruzzese, E, Raia, V, Gaudiello, G, Polito, G, Buccigrossi, V, Formicola, V, *et al.* Intestinal inflammation is a frequent feature of cystic fibrosis and is reduced by probiotic administration. *Aliment Pharmacol Ther* 20, 813-819 (2004).
167. del Campo, R, Garriga, M, Perez-Aragon, A, Guallarte, P, Lamas, A, Maiz, L, *et al.* Improvement of digestive health and reduction in proteobacterial populations in the gut microbiota of cystic fibrosis patients using a Lactobacillus reuteri probiotic preparation: a double blind prospective study. *J Cyst Fibros* 13, 716-722 (2014).
168. Di Nardo, G, Oliva, S, Menichella, A, Pistelli, R, De Biase, RV, Patriarchi, F, *et al.* Lactobacillus reuteri ATCC55730 in cystic fibrosis. *J Pediatr Gastroenterol Nutr* 58, 81-86 (2014).
169. Fallahi, G, Motamed, F, Yousefi, A, Shafieyoun, A, Najafi, M, Khodadad, A, *et al.* The effect of probiotics on fecal calprotectin in patients with cystic fibrosis. *Turk J Pediatr* 55, 475-478 (2013).
170. Jafari, SA, Mehdizadeh-Hakkak, A, Kianifar, HR, Hebrani, P, Ahanchian, H & Abbasnejad, E. Effects of probiotics on quality of life in children with cystic fibrosis; a randomized controlled trial. *Iran J Pediatr* 23, 669-674 (2013).
171. Weiss, B, Bujanover, Y, Yahav, Y, Vilozni, D, Fireman, E & Efrati, O. Probiotic supplementation affects pulmonary exacerbations in patients with cystic fibrosis: a pilot study. *Pediatr Pulmonol* 45, 536-540 (2010).
172. Visca, A, Bishop, CT, Hilton, S & Hudson, VM. Oral reduced L-glutathione improves growth in pediatric cystic fibrosis patients. *J Pediatr Gastroenterol Nutr* 60, 802-810 (2015).
173. Conrad, C, Lymp, J, Thompson, V, Dunn, C, Davies, Z, Chatfield, B, *et al.* Long-term treatment with oral N-acetylcysteine: affects lung function but not sputum inflammation in cystic fibrosis subjects. A phase II randomized placebo-controlled trial. *J Cyst Fibros* 14, 219-227 (2015).
174. Dauletbaev, N, Fischer, P, Aulbach, B, Gross, J, Kusche, W, Thyroff-Friesinger, U, *et al.* A phase II study on safety and efficacy of high-dose N-acetylcysteine in patients with cystic fibrosis. *Eur J Med Res* 14, 352-358 (2009).
175. Tirouvanziam, R, Conrad, CK, Bottiglieri, T, Herzenberg, LA & Moss, RB. High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis. *Proc Natl Acad Sci U S A* 103, 4628-4633 (2006).
176. Visca, A, Bishop, CT, Hilton, SC & Hudson, VM. Improvement in clinical markers in CF patients using a reduced glutathione regimen: an uncontrolled, observational study. *J Cyst Fibros* 7, 433-436 (2008).
177. Smyth, AR, Cifelli, PM, Ortori, CA, Righetti, K, Lewis, S, Erskine, P, *et al.* Garlic as an inhibitor of Pseudomonas aeruginosa quorum sensing in cystic fibrosis--a pilot randomized controlled trial. *Pediatr Pulmonol* 45, 356-362 (2010).
178. Hasse, JM. Diet therapy for organ transplantation. A problem-based approach. *Nurs Clin North Am* 32, 863-880 (1997).
179. Anthony, H, Catto-Smith, A, Phelan, P & Paxton, S. Current approaches to the nutritional management of cystic fibrosis in Australia. *J Paediatr Child Health* 34, 170-174 (1998).
180. King, SJ, Collins, CE, Crowder, T, Matson, AG & Volders, E. Nutritional management of cystic fibrosis in Australia and New Zealand. *Nutrition and Dietetics* 65, 253 - 258 (2008).
181. PORT CF. Data Registry. (Cystic Fibrosis New Zealand, unpublished).
182. Dietitians Board. Code of Ethics and Conduct for Dietitians. (Dietitians Board, Wellington, New Zealand, 2014). <http://www.dietitiansboard.org.nz/>
183. National Health and Medical Research Council. Levels of Evidence and Grades for recommendations for Developers of Guidelines. (National Health and Medical Research Council, Commonwealth of Australia, Canberra, 2009). [https://www.nhmrc.gov.au/files\\_nhmrc/file/guidelines/developers/nhmrc\\_levels\\_grades\\_evidence\\_120423.pdf](https://www.nhmrc.gov.au/files_nhmrc/file/guidelines/developers/nhmrc_levels_grades_evidence_120423.pdf)
184. American Dietetic Association. ADA Evidence Analysis Manual. (American Dietetic Association, Chicago, USA, 2005). [http://www.adaevidencelibrary.com/files/ADA%20Evidence%20Analysis%20Manual\\_ed3c%20Nov%202005.pdf](http://www.adaevidencelibrary.com/files/ADA%20Evidence%20Analysis%20Manual_ed3c%20Nov%202005.pdf)
185. Daitch, V, Babich, T, Singer, P & Leibovici, L. Quality of Reporting Nutritional Randomized Controlled Trials in Patients with Cystic Fibrosis. *J Pediatr Gastroenterol Nutr* (2016).
186. Rosenstein, BJ & Cutting, GR. The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel. *J Pediatr* 132, 589-595 (1998).

187. Davis, PB, Drumm, M & Konstan, MW. Cystic fibrosis. *Am J Respir Crit Care Med* 154, 1229-1256 (1996).
188. Cystic Fibrosis Australia. Cystic Fibrosis In Australia 2014 -17th Annual Report from the Australian Cystic Fibrosis Data Registry. (North Ryde, Australia, 2014). [https://www.cysticfibrosis.org.au/media/wysiwyg/CF-Australia/medical-documents/CFA\\_DataRegistryReport\\_2014\\_Final.pdf](https://www.cysticfibrosis.org.au/media/wysiwyg/CF-Australia/medical-documents/CFA_DataRegistryReport_2014_Final.pdf)
189. Cystic Fibrosis Association of New Zealand. PORT CF NZ National Data Registry 2014. (Christchurch, New Zealand, 2014).
190. Solomon, M, Bozic, M & Mascarenhas, MR. Nutritional Issues in Cystic Fibrosis. *Clin Chest Med* 37, 97-107 (2016).
191. Massie, RJ, Curnow, L, Glazner, J, Armstrong, DS & Francis, I. Lessons learned from 20 years of newborn screening for cystic fibrosis. *Med J Aust* 196, 67-70 (2012).
192. Farrell, PM, Rosenstein, BJ, White, TB, Accurso, FJ, Castellani, C, Cutting, GR, *et al.* Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. *J Pediatr* 153, S4-S14 (2008).
193. Coakley, J, Scott, S, Mackay, R, Greaves, R, Jolly, L, Massie, J, *et al.* Sweat testing for cystic fibrosis: standards of performance in Australasia. *Ann Clin Biochem* 46, 332-337 (2009).
194. Corey, M, McLaughlin, FJ, Williams, M & Levison, H. A comparison of survival, growth, and pulmonary function in patients with cystic fibrosis in Boston and Toronto. *J Clin Epidemiol* 41, 583-591 (1988).
195. Lai, HC, Corey, M, FitzSimmons, S, Kosorok, MR & Farrell, PM. Comparison of growth status of patients with cystic fibrosis between the United States and Canada. *Am J Clin Nutr* 69, 531-538 (1999).
196. Konstan, MW, Butler, SM, Wohl, ME, Stoddard, M, Matousek, R, Wagener, JS, *et al.* Growth and nutritional indexes in early life predict pulmonary function in cystic fibrosis. *J Pediatr* 142, 624-630 (2003).
197. Yen, EH, Quinton, H & Borowitz, D. Better nutritional status in early childhood is associated with improved clinical outcomes and survival in patients with cystic fibrosis. *J Pediatr* 162, 530-535.e531 (2013).
198. Steinkamp, G & Wiedemann, B. Relationship between nutritional status and lung function in cystic fibrosis: cross sectional and longitudinal analyses from the German CF quality assurance (CFQA) project. *Thorax* 57, 596-601 (2002).
199. Stephenson, AL, Mannik, LA, Walsh, S, Brotherwood, M, Robert, R, Darling, PB, *et al.* Longitudinal trends in nutritional status and the relation between lung function and BMI in cystic fibrosis: a population-based cohort study. *Am J Clin Nutr* 97, 872-877 (2013).
200. Peterson, ML, Jacobs, DR, Jr. & Milla, CE. Longitudinal changes in growth parameters are correlated with changes in pulmonary function in children with cystic fibrosis. *Pediatrics* 112, 588-592 (2003).
201. Konstan, MW, Morgan, WJ, Butler, SM, Pasta, DJ, Craib, ML, Silva, SJ, *et al.* Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. *J Pediatr* 151, 134-139, 139.e131 (2007).
202. Borowitz, D, Baker, RD & Stallings, V. Consensus report on nutrition for pediatric patients with cystic fibrosis. *J Pediatr Gastroenterol Nutr* 35, 246-259 (2002).
203. Collins, CE, MacDonald-Wicks, L, Rowe, S, O'Loughlin, EV & Henry, RL. Normal growth in cystic fibrosis associated with a specialised centre. *Arch Dis Child* 81, 241-246 (1999).
204. Richardson, I, Nyulasi, I, Cameron, K, Ball, M & Wilson, J. Nutritional status of an adult cystic fibrosis population. *Nutrition* 16, 255-259 (2000).
205. Cystic Fibrosis Australia. Cystic Fibrosis in Australia 2004 - Annual report from the Australian Cystic Fibrosis Data Registry. (North Ryde, Australia, 2004).
206. Stettler, N, Kawchak, DA, Boyle, LL, Propert, KJ, Scanlin, TF, Stallings, VA, *et al.* Prospective evaluation of growth, nutritional status, and body composition in children with cystic fibrosis. *Am J Clin Nutr* 72, 407-413 (2000).
207. White, H, Wolfe, SP, Foy, J, Morton, A, Conway, SP & Brownlee, KB. Nutritional intake and status in children with cystic fibrosis: does age matter? *J Pediatr Gastroenterol Nutr* 44, 116-123 (2007).
208. Buntain, HM, Greer, RM, Wong, JC, Schluter, PJ, Batch, J, Lewindon, P, *et al.* Pubertal development and its influences on bone mineral density in Australian children and adolescents with cystic fibrosis. *J Paediatr Child Health* 41, 317-322 (2005).
209. Williams, JE, Wells, JC, Benden, C, Jaffe, A, Suri, R, Wilson, CM, *et al.* Body composition assessed by the 4-component model and association with lung function in 6-12-y-old children with cystic fibrosis. *Am J Clin Nutr* 92, 1332-1343 (2010).
210. Stapleton, D, Kerr, D, Gurrin, L, Sherriff, J & Sly, P. Height and weight fail to detect early signs of malnutrition in children with cystic fibrosis. *J Pediatr Gastroenterol Nutr* 33, 319-325 (2001).
211. Ahmed, ML, Ong, KK, Thomson, AH & Dunger, DB. Reduced gains in fat and fat-free mass, and elevated leptin levels in children and adolescents with cystic fibrosis. *Acta Paediatr* 93, 1185-1191 (2004).
212. Richards, ML, Bell, SC, Edmiston, KA & Davies, PS. Assessment of bioelectrical impedance analysis for the prediction of total body water in cystic fibrosis. *Asia Pac J Clin Nutr* 12, 161-165 (2003).
213. King, SJ, Nyulasi, IB, Strauss, BJ, Kotsimbos, T, Bailey, M & Wilson, JW. Fat-free mass depletion in cystic fibrosis: associated with lung disease severity but poorly detected by body mass index. *Nutrition* 26, 753-759 (2010).
214. Sermet-Gaudelus, I, Souberbielle, JC, Azhar, I, Ruiz, JC, Magnine, P, Colomb, V, *et al.* Insulin-like growth factor I correlates with lean body mass in cystic fibrosis patients. *Arch Dis Child* 88, 956-961 (2003).





215. McNaughton, SA, Shepherd, RW, Greer, RG, Cleghorn, GJ & Thomas, BJ. Nutritional status of children with cystic fibrosis measured by total body potassium as a marker of body cell mass: lack of sensitivity of anthropometric measures. *J Pediatr* 136, 188-194 (2000).
216. Sood, M, Adams, JE & Mughal, MZ. Lean body mass in children with cystic fibrosis. *Arch Dis Child* 88, 836 (2003).
217. Groeneweg, M, Tan, S, Boot, AM, de Jongste, JC, Bouquet, J & Sinaasappel, M. Assessment of nutritional status in children with cystic fibrosis: conventional anthropometry and bioelectrical impedance analysis. A cross-sectional study in Dutch patients. *J Cyst Fibros* 1, 276-280 (2002).
218. Pinet, C, Cassart, M, Scillia, P, Lamotte, M, Knoop, C, Casimir, G, *et al.* Function and bulk of respiratory and limb muscles in patients with cystic fibrosis. *Am J Respir Crit Care Med* 168, 989-994 (2003).
219. Oliveira, G, Oliveira, C, Gaspar, I, Porras, N, Martin-Nunez, G, Rubio, E, *et al.* Fat-free mass depletion and inflammation in patients with bronchiectasis. *J Acad Nutr Diet* 112, 1999-2006 (2012).
220. Pedreira, CC, Robert, RG, Dalton, V, Oliver, MR, Carlin, JB, Robinson, P, *et al.* Association of body composition and lung function in children with cystic fibrosis. *Pediatr Pulmonol* 39, 276-280 (2005).
221. Alvarez, JA, Ziegler, TR, Millson, EC & Stecenko, AA. Body composition and lung function in cystic fibrosis and their association with adiposity and normal-weight obesity. *Nutrition* 32, 447-452 (2016).
222. Bianchi, ML, Romano, G, Saraifoger, S, Costantini, D, Limonta, C & Colombo, C. BMD and body composition in children and young patients affected by cystic fibrosis. *J Bone Miner Res* 21, 388-396 (2006).
223. Ionescu, AA, Nixon, LS, Evans, WD, Stone, MD, Lewis-Jenkins, V, Chatham, K, *et al.* Bone density, body composition, and inflammatory status in cystic fibrosis. *Am J Respir Crit Care Med* 162, 789-794 (2000).
224. Ionescu, AA, Nixon, LS, Luzio, S, Lewis-Jenkins, V, Evans, WD, Stone, MD, *et al.* Pulmonary function, body composition, and protein catabolism in adults with cystic fibrosis. *Am J Respir Crit Care Med* 165, 495-500 (2002).
225. Bolton, CE, Ionescu, AA, Evans, WD, Pettit, RJ & Shale, DJ. Altered tissue distribution in adults with cystic fibrosis. *Thorax* 58, 885-889 (2003).
226. Ionescu, AA, Evans, WD, Pettit, RJ, Nixon, LS, Stone, MD & Shale, DJ. Hidden depletion of fat-free mass and bone mineral density in adults with cystic fibrosis. *Chest* 124, 2220-2228 (2003).
227. King, SJ, Nyulasi, IB, Bailey, M, Kotsimbos, T & Wilson, JW. Loss of fat-free mass over four years in adult cystic fibrosis is associated with high serum interleukin-6 levels but not tumour necrosis factor-alpha. *Clin Nutr* 33, 150-155 (2014).
228. Ionescu, AA, Nixon, LS & Shale, DJ. Cellular proteolysis and systemic inflammation during exacerbation in cystic fibrosis. *J Cyst Fibros* 3, 253-258 (2004).
229. Lai, HC, Kosorok, MR, Sondel, SA, Chen, ST, FitzSimmons, SC, Green, CG, *et al.* Growth status in children with cystic fibrosis based on the National Cystic Fibrosis Patient Registry data: evaluation of various criteria used to identify malnutrition. *J Pediatr* 132, 478-485 (1998).
230. Buntain, HM, Schluter, PJ, Bell, SC, Greer, RM, Wong, JC, Batch, J, *et al.* Controlled longitudinal study of bone mass accrual in children and adolescents with cystic fibrosis. *Thorax* 61, 146-154 (2006).
231. Gaskin, KJ, Durie, PR, Lee, L, Hill, R & Forstner, GG. Colipase and lipase secretion in childhood-onset pancreatic insufficiency. Delineation of patients with steatorrhea secondary to relative colipase deficiency. *Gastroenterology* 86, 1-7 (1984).
232. Ooi, CY, Dorfman, R, Cipolli, M, Gonska, T, Castellani, C, Keenan, K, *et al.* Type of CFTR mutation determines risk of pancreatitis in patients with cystic fibrosis. *Gastroenterology* 140, 153-161 (2011).
233. Assis, DN & Freedman, SD. Gastrointestinal Disorders in Cystic Fibrosis. *Clin Chest Med* 37, 109-118 (2016).
234. Ooi, CY, Jeyaruban, C, Lau, J, Katz, T, Matson, A, Bell, SC, *et al.* High ambient temperature and risk of intestinal obstruction in cystic fibrosis. *J Paediatr Child Health* 52, 430-435 (2016).
235. Dhaliwal, J, Leach, S, Katz, T, Nahidi, L, Pang, T, Lee, JM, *et al.* Intestinal inflammation and impact on growth in children with cystic fibrosis. *J Pediatr Gastroenterol Nutr* 60, 521-526 (2015).
236. Ooi, CY & Durie, PR. Cystic fibrosis from the gastroenterologist's perspective. *Nat Rev Gastroenterol Hepatol* 13, 175-185 (2016).
237. Lisowska, A, Wojtowicz, J & Walkowiak, J. Small intestine bacterial overgrowth is frequent in cystic fibrosis: combined hydrogen and methane measurements are required for its detection. *Acta Biochim Pol* 56, 631-634 (2009).
238. Moran, A, Pillay, K, Becker, DJ & Acerini, CL. ISPAD Clinical Practice Consensus Guidelines 2014. Management of cystic fibrosis-related diabetes in children and adolescents. *Pediatr Diabetes* 15 Suppl 20, 65-76 (2014).
239. Milla, CE, Billings, J & Moran, A. Diabetes is associated with dramatically decreased survival in female but not male subjects with cystic fibrosis. *Diabetes Care* 28, 2141-2144 (2005).
240. Sims, EJ, Green, MW & Mehta, A. Decreased lung function in female but not male subjects with established cystic fibrosis-related diabetes. *Diabetes Care* 28, 1581-1587 (2005).
241. Worgall, TS. Lipid metabolism in cystic fibrosis. *Curr Opin Clin Nutr Metab Care* 12, 105-109 (2009).
242. Peretti, N, Roy, CC, Drouin, E, Seidman, E, Brochu, P, Casimir, G, *et al.* Abnormal intracellular lipid processing contributes to fat malabsorption in cystic fibrosis patients. *Am J Physiol Gastrointest Liver Physiol* 290, G609-615 (2006).

243. Mahadeva, R, Webb, K, Westerbeek, RC, Carroll, NR, Dodd, ME, Bilton, D, *et al.* Clinical outcome in relation to care in centres specialising in cystic fibrosis: cross sectional study. *Bmj* 316, 1771-1775 (1998).
244. Kerem, E, Conway, S, Elborn, S & Heijerman, H. Standards of care for patients with cystic fibrosis: a European consensus. *J Cyst Fibros* 4, 7-26 (2005).
245. Graham, C, Kench, A, Brown, S & Cooper, P. The Introduction of a Nutrition Education Assistant Position to the Cystic Fibrosis Team at the Children's Hospital Westmead,. in *10th Australian Cystic Fibrosis Conference* (Auckland, New Zealand, 2013).
246. McDonald, CM. Validation of a nutrition risk screening tool for children and adolescents with cystic fibrosis ages 2-20 years. *J Pediatr Gastroenterol Nutr* 46, 438-446 (2008).
247. McDonald, CM. Nutrition Screening and Diagnosis with Early, Appropriate Interventions Are Critical Components of Cystic Fibrosis Management. *J Acad Nutr Diet* 116, 771-773 (2016).
248. Souza Dos Santos Simon, MI, Forte, GC, da Silva Pereira, J, da Fonseca Andrade Procianoy, E & Drehmer, M. Validation of a Nutrition Screening Tool for Pediatric Patients with Cystic Fibrosis. *J Acad Nutr Diet* 116, 813-818 (2016).
249. Smyth, AR, Bell, SC, Bojcin, S, Bryon, M, Duff, A, Flume, P, *et al.* European Cystic Fibrosis Society Standards of Care: Best Practice guidelines. *J Cyst Fibros* 13 Suppl 1, S23-42 (2014).
250. Conway, S, Balfour-Lynn, IM, De Rijcke, K, Drevinek, P, Foweraker, J, Havermans, T, *et al.* European Cystic Fibrosis Society Standards of Care: Framework for the Cystic Fibrosis Centre. *J Cyst Fibros* 13 Suppl 1, S3-22 (2014).
251. Gibson, RS. *Principles of Nutritional Assessment*, (Oxford University Press, New York, 2005).
252. Yankaskas, JR, Marshall, BC, Sufian, B, Simon, RH & Rodman, D. Cystic fibrosis adult care: consensus conference report. *Chest* 125, 1s-39s (2004).
253. New Zealand Ministry of Health. Fact sheet 2: About the NZ-WHO Growth Charts. (New Zealand Ministry of Health and World Health Organization, 2010). <http://www.health.govt.nz/system/files/documents/pages/factsheet-2-growth-charts-well-child.pdf>
254. National Health and Medical Research Council. Australian Dietary Guidelines Summary. (Australian Government, Canberra, Australia, 2013).
255. de Onis, M, Garza, C, Onyango, AW & Borghi, E. Comparison of the WHO child growth standards and the CDC 2000 growth charts. *J Nutr* 137, 144-148 (2007).
256. Zhang, Z, Shoff, SM & Lai, HJ. Comparing the Use of Centers for Disease Control and Prevention and World Health Organization Growth Charts in Children with Cystic Fibrosis through 2 Years of Age. *J Pediatr* 167, 1089-1095 (2015).
257. Usatin, D, Yen, EH, McDonald, C, Asfour, F, Pohl, J & Robson, J. Differences between WHO AND CDC early growth measurements in the assessment of Cystic Fibrosis clinical outcomes. *J Cyst Fibros* (2016).
258. Cystic Fibrosis Foundation. Use and Interpretation of World Health Organization Growth Charts in the Context of Achieving Optimal Growth for Children with CF: Birth to 24 months. (Unpublished, 2015).
259. Schutz, Y, Kyle, UU & Pichard, C. Fat-free mass index and fat mass index percentiles in Caucasians aged 18-98 y. *Int J Obes Relat Metab Disord* 26, 953-960 (2002).
260. Wells, JC. A critique of the expression of paediatric body composition data. *Arch Dis Child* 85, 67-72 (2001).
261. Cederholm, T, Bosaeus, I, Barazzoni, R, Bauer, J, Van Gossum, A, Klek, S, *et al.* Diagnostic criteria for malnutrition - An ESPEN Consensus Statement. *Clin Nutr* 34, 335-340 (2015).
262. King, SJ, Topliss, DJ, Kotsimbos, T, Nyulasi, IB, Bailey, M, Ebeling, PR, *et al.* Reduced bone density in cystic fibrosis: DeltaF508 mutation is an independent risk factor. *Eur Respir J* 25, 54-61 (2005).
263. Murphy, AJ, Buntain, HM, Wong, JC, Greer, RM, Wainwright, CE & Davies, PS. The use of air displacement plethysmography in children and adolescents with cystic fibrosis. *Eur J Clin Nutr* 58, 985-989 (2004).
264. Plank, LD. Dual-energy X-ray absorptiometry and body composition. *Curr Opin Clin Nutr Metab Care* 8, 305-309 (2005).
265. Mulasi, U, Kuchnia, AJ, Cole, AJ & Earthman, CP. Bioimpedance at the bedside: current applications, limitations, and opportunities. *Nutr Clin Pract* 30, 180-193 (2015).
266. Baracos, V, Caserotti, P, Earthman, CP, Fields, D, Gallagher, D, Hall, KD, *et al.* Advances in the science and application of body composition measurement. *JPENJ Parenter Enteral Nutr* 36, 96-107 (2012).
267. White, JV, Guenter, P, Jensen, G, Malone, A & Schofield, M. Consensus statement: Academy of Nutrition and Dietetics and American Society for Parenteral and Enteral Nutrition: characteristics recommended for the identification and documentation of adult malnutrition (undernutrition). *JPENJ Parenter Enteral Nutr* 36, 275-283 (2012).
268. Carpenter, A, Pencharz, P & Mouzaki, M. Accurate estimation of energy requirements of young patients. *J Pediatr Gastroenterol Nutr* 60, 4-10 (2015).
269. Psota, T & Chen, KY. Measuring energy expenditure in clinical populations: rewards and challenges. *Eur J Clin Nutr* 67, 436-442 (2013).
270. Wooley, JA. Indirect calorimetry: applications in practice. *Respir Care Clin N Am* 12, 619-633 (2006).
271. Compher, C, Frankenfield, D, Keim, N & Roth-Yousey, L. Best practice methods to apply to measurement of resting metabolic rate in adults: a systematic review. *J Am Diet Assoc* 106, 881-903 (2006).



272. National Health and Medical Research Council. Recommended Dietary Intakes for use in Australia. (National Health and Medical Research Council, Australian Government, Australia, 1991). <https://www.nhmrc.gov.au/guidelines-publications/n6>
273. Schofield, WN. Predicting basal metabolic rate, new standards and review of previous work. *Hum Nutr Clin Nutr* 39 Suppl 1, 5-41 (1985).
274. Hollander, FM, De Roos, NM, De Vries, JH & Van Berkhout, FT. Assessment of nutritional status in adult patients with cystic fibrosis: whole-body bioimpedance vs body mass index, skinfolds, and leg-to-leg bioimpedance. *J Am Diet Assoc* 105, 549-555 (2005).
275. Hollander, FM, Kok, A, de Roos, NM, Belle-van Meerkerk, G & van de Graaf, EA. Prediction Equations Underestimate Resting Energy Expenditure in Patients With End-Stage Cystic Fibrosis. *Nutr Clin Pract* 32, 116-121 (2017).
276. McCloskey, M, Redmond, AO, Pyper, S, McCabe, C, Westerterp, KR & Elborn, JS. Total energy expenditure in stable patients with cystic fibrosis. *Clin Nutr* 20, 235-241 (2001).
277. Jensen, GL, Hsiao, PY & Wheeler, D. Adult nutrition assessment tutorial. *JPEN J Parenter Enteral Nutr* 36, 267-274 (2012).
278. Hanna, RM & Weiner, DJ. Overweight and obesity in patients with cystic fibrosis: a center-based analysis. *Pediatr Pulmonol* 50, 35-41 (2015).
279. Sinaasappel, M, Stern, M, Littlewood, J, Wolfe, S, Steinkamp, G, Heijerman, HG, *et al.* Nutrition in patients with cystic fibrosis: a European Consensus. *J Cyst Fibros* 1, 51-75 (2002).
280. Nixon, LS, Yung, B, Bell, SC, Elborn, JS & Shale, DJ. Circulating immunoreactive interleukin-6 in cystic fibrosis. *Am J Respir Crit Care Med* 157, 1764-1769 (1998).
281. Wood, LG, Gibson, PG & Garg, ML. Circulating markers to assess nutritional therapy in cystic fibrosis. *Clin Chim Acta* 353, 13-29 (2005).
282. Vic, P, Ategbo, S, Gottrand, F, Launay, V, Loeuille, GA, Elian, JC, *et al.* Nutritional impact of antipseudomonas intravenous antibiotic courses in cystic fibrosis. *Arch Dis Child* 76, 437-440 (1997).
283. Quick, VM, McWilliams, R & Byrd-Bredbenner, C. Case-control study of disturbed eating behaviors and related psychographic characteristics in young adults with and without diet-related chronic health conditions. *Eat Behav* 13, 207-213 (2012).
284. National Centre for Classification in Health. National Centre for Classification in Health - ICD-10. (The University of Sydney, Australia, 2016). <http://sydney.edu.au/health-sciences/ncch/>
285. UK Cystic Fibrosis Trust Nutrition Working Group. Nutritional management of cystic fibrosis. (Cystic Fibrosis Trust, United Kingdom, 2002).
286. Crist, W & Napier-Phillips, A. Mealtime behaviors of young children: a comparison of normative and clinical data. *J Dev Behav Pediatr* 22, 279-286 (2001).
287. Opiari-Arrigan, L, Powers, SW, Quittner, AL & Stark, LJ. Mealtime problems predict outcome in clinical trial to improve nutrition in children with CF. *Pediatr Pulmonol* 45, 78-82 (2010).
288. Nasr, SZ & Drury, D. Appetite stimulants use in cystic fibrosis. *Pediatr Pulmonol* 43, 209-219 (2008).
289. Chinuck, RS, Fortnum, H & Baldwin, DR. Appetite stimulants in cystic fibrosis: a systematic review. *J Hum Nutr Diet* 20, 526-537 (2007).
290. Marchand, V, Baker, SS, Stark, TJ & Baker, RD. Randomized, double-blind, placebo-controlled pilot trial of megestrol acetate in malnourished children with cystic fibrosis. *J Pediatr Gastroenterol Nutr* 31, 264-269 (2000).
291. Eubanks, V, Koppersmith, N, Wooldridge, N, Clancy, JP, Lyrene, R, Arani, RB, *et al.* Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis. *J Pediatr* 140, 439-444 (2002).
292. Homnick, DN, Homnick, BD, Reeves, AJ, Marks, JH, Pimentel, RS & Bonnema, SK. Cyproheptadine is an effective appetite stimulant in cystic fibrosis. *Pediatr Pulmonol* 38, 129-134 (2004).
293. Epifanio, M, Marostica, PC, Mattiello, R, Feix, L, Nejedlo, R, Fischer, GB, *et al.* A randomized, double-blind, placebo-controlled trial of cyproheptadine for appetite stimulation in cystic fibrosis. *J Pediatr (Rio J)* 88, 155-160 (2012).
294. Schwarzenberg, SJ, Hempstead, SE, McDonald, CM, Powers, SW, Wooldridge, J, Blair, S, *et al.* Enteral tube feeding for individuals with cystic fibrosis: Cystic Fibrosis Foundation evidence-informed guidelines. *J Cyst Fibros* (2016).
295. Royal Children's Hospital. Enteral feeding and medication administration. (Royal Children's Hospital, Melbourne, Australia, 2015). [http://www.rch.org.au/rchcpg/hospital\\_clinical\\_guideline\\_index/Enteral\\_feeding\\_and\\_medication\\_administration/](http://www.rch.org.au/rchcpg/hospital_clinical_guideline_index/Enteral_feeding_and_medication_administration/)
296. Panagopoulou, P, Fotoulaki, M, Nikolaou, A & Nousia-Arvanitakis, S. Prevalence of malnutrition and obesity among cystic fibrosis patients. *Pediatr Int* 56, 89-94 (2014).
297. Schols, AM, Broekhuizen, R, Weling-Scheepers, CA & Wouters, EF. Body composition and mortality in chronic obstructive pulmonary disease. *Am J Clin Nutr* 82, 53-59 (2005).
298. National Health and Medical Research Council. Clinical Practice Guidelines for the Management of Overweight and Obesity in Adults, Adolescents and Children in Australia. (National Health and Medical Research Council, Australian Government, Australia, 2013). <https://www.nhmrc.gov.au/guidelines-publications/n57>
299. New Zealand Ministry of Health Clinical Trials Research Unit. Clinical Guidelines for Weight Management in New Zealand Adults. (Ministry of Health, Wellington, New Zealand, 2009). <https://www.health.govt.nz/system/files/documents/publications/weight-management-adults-guidelines.pdf>

300. New Zealand Ministry of Health. Clinical Guidelines for Weight Management in New Zealand Children and Young People. (Ministry of Health, Wellington, New Zealand, 2016). <http://www.health.govt.nz/publication/clinical-guidelines-weight-management-new-zealand-children-and-young-people>
301. Thomson, MA, Quirk, P, Swanson, CE, Thomas, BJ, Holt, TL, Francis, PJ, *et al.* Nutritional growth retardation is associated with defective lung growth in cystic fibrosis: a preventable determinant of progressive pulmonary dysfunction. *Nutrition* 11, 350-354 (1995).
302. Yen, EH & Radmer Leonard, A. *Nutrition in Cystic Fibrosis: A guide for clinicians (Nutrition and Health)*, (Humana Press, 2015).
303. Wideman, L, Baker, CF, Brown, PK, Consitt, LA, Ambrosius, WT & Schechter, MS. Substrate utilization during and after exercise in mild cystic fibrosis. *Med Sci Sports Exerc* 41, 270-278 (2009).
304. Spicher, V, Roulet, M & Schutz, Y. Assessment of total energy expenditure in free-living patients with cystic fibrosis. *J Pediatr* 118, 865-872 (1991).
305. Shepherd, RW, Greer, RM, McNaughton, SA, Wotton, M & Cleghorn, GJ. Energy expenditure and the body cell mass in cystic fibrosis. *Nutrition* 17, 22-25 (2001).
306. Richards, ML, Davies, PS & Bell, SC. Energy cost of physical activity in cystic fibrosis. *Eur J Clin Nutr* 55, 690-697 (2001).
307. Ward, SA, Tomezsko, JL, Holsclaw, DS & Paolone, AM. Energy expenditure and substrate utilization in adults with cystic fibrosis and diabetes mellitus. *Am J Clin Nutr* 69, 913-919 (1999).
308. Wiskin, AE, Davies, JH, Wootton, SA & Beattie, RM. Energy expenditure, nutrition and growth. *Arch Dis Child* 96, 567-572 (2011).
309. Fried, MD, Durie, PR, Tsui, LC, Corey, M, Levison, H & Pencharz, PB. The cystic fibrosis gene and resting energy expenditure. *J Pediatr* 119, 913-916 (1991).
310. Zemel, BS, Kawchak, DA, Cnaan, A, Zhao, H, Scanlin, TF & Stallings, VA. Prospective evaluation of resting energy expenditure, nutritional status, pulmonary function, and genotype in children with cystic fibrosis. *Pediatr Res* 40, 578-586 (1996).
311. Fuster, CO, Fuster, GO, Galindo, AD, Galo, AP, Verdugo, JM & Lozano, FM. [Analysis of energy expenditure in adults with cystic fibrosis: comparison of indirect calorimetry and prediction equations]. *Arch Bronconeumol* 43, 366-372 (2007).
312. Stallings, VA, Fung, EB, Hofley, PM & Scanlin, TF. Acute pulmonary exacerbation is not associated with increased energy expenditure in children with cystic fibrosis. *J Pediatr* 132, 493-499 (1998).
313. Gaskin, KJ. Nutritional care in children with cystic fibrosis: are our patients becoming better? *Eur J Clin Nutr* 67, 558-564 (2013).
314. Walkowiak, J & Przyslawski, J. Five-year prospective analysis of dietary intake and clinical status in malnourished cystic fibrosis patients. *J Hum Nutr Diet* 16, 225-231 (2003).
315. Iqbal, J & Hussain, MM. Intestinal lipid absorption. *Am J Physiol Endocrinol Metab* 296, E1183-1194 (2009).
316. You, YQ, Ling, PR, Qu, JZ & Bistrrian, BR. Effects of medium-chain triglycerides, long-chain triglycerides, or 2-monododecanoin on fatty acid composition in the portal vein, intestinal lymph, and systemic circulation in rats. *JPEN J Parenter Enteral Nutr* 32, 169-175 (2008).
317. Koletzko, S & Reinhardt, D. Nutritional challenges of infants with cystic fibrosis. *Early Hum Dev* 65 Suppl, S53-61 (2001).
318. Gavin, J, Ellis, J, Dewar, AL, Rolles, CJ & Connett, GJ. Dietary fibre and the occurrence of gut symptoms in cystic fibrosis. *Arch Dis Child* 76, 35-37 (1997).
319. National Health and Medical Research Council. Fat. (National Health and Medical Research Council and Department of Health, Australian Government, Australia, 2015). <https://www.eatforhealth.gov.au/food-essentials/fat-salt-sugars-and-alcohol/fat>
320. Nutrition Australia. Fact sheet:Fibre. (Nutrition Australia, Victoria Australia, 2014). <http://www.nutritionaustralia.org/national/resource/fibre>
321. Better Health Channel. Fibre in Food. (Victoria State Government, Victoria, Australia, 2014). <https://www.betterhealth.vic.gov.au/health/healthyliving/fibre-in-food>
322. Kien, CL, Zipf, WB, Horswill, CA, Denne, SC, McCoy, KS & O'Doriso, TM. Effects of feeding on protein turnover in healthy children and in children with cystic fibrosis. *Am J Clin Nutr* 64, 608-614 (1996).
323. Engelen, MP, Com, G, Wolfe, RR & Deutz, NE. Dietary essential amino acids are highly anabolic in pediatric patients with cystic fibrosis. *J Cyst Fibros* 12, 445-453 (2013).
324. Engelen, MP, Com, G & Deutz, NE. Protein is an important but undervalued macronutrient in the nutritional care of patients with cystic fibrosis. *Curr Opin Clin Nutr Metab Care* 17, 515-520 (2014).
325. Ellis, L, Kalnins, D, Corey, M, Brennan, J, Pencharz, P & Durie, P. Do infants with cystic fibrosis need a protein hydrolysate formula? A prospective, randomized, comparative study. *J Pediatr* 132, 270-276 (1998).
326. Erskine, JM, Lingard, CD, Sontag, MK & Accurso, FJ. Enteral nutrition for patients with cystic fibrosis: comparison of a semi-elemental and nonelemental formula. *J Pediatr* 132, 265-269 (1998).
327. Geukers, VG, Oudshoorn, JH, Taminiu, JA, van der Ent, CK, Schilte, P, Ruiters, AF, *et al.* Short-term protein intake and stimulation of protein synthesis in stunted children with cystic fibrosis. *Am J Clin Nutr* 81, 605-610 (2005).
328. Pandit, C, Graham, C, Selvadurai, H, Gaskin, K, Cooper, P & van Asperen, P. Festival food coma in cystic fibrosis. *Pediatr Pulmonol* 48, 725-727 (2013).





329. Ministry of Health. Food and Nutrition Guidelines for Healthy Infants and Toddlers (Aged 0 - 2): A background paper - Partially revised December 2012. (Ministry of Health, New Zealand Government, Wellington, New Zealand, 2008). <http://www.health.govt.nz/publication/food-and-nutrition-guidelines-healthy-infants-and-toddlers-aged-0-2-background-paper-partially>
330. Potgieter, S. Sport Nutrition: A review of the latest guidelines for exercise and sport nutrition, the International Olympic Committee and the International Society for Sports Nutrition. *26*(1), 6-16 (2013).
331. Rodriguez, NR, Di Marco, NM & Langley, S. American College of Sports Medicine position stand. Nutrition and athletic performance. *Med Sci Sports Exerc* 41, 709-731 (2009).
332. Maqbool, A, Schall, JI, Garcia-Espana, JF, Zemel, BS, Strandvik, B & Stallings, VA. Serum linoleic acid status as a clinical indicator of essential fatty acid status in children with cystic fibrosis. *J Pediatr Gastroenterol Nutr* 47, 635-644 (2008).
333. Roulet, M, Frascarolo, P, Rappaz, I & Pilet, M. Essential fatty acid deficiency in well nourished young cystic fibrosis patients. *Eur J Pediatr* 156, 952-956 (1997).
334. Maqbool, A, Schall, JI, Gallagher, PR, Zemel, BS, Strandvik, B & Stallings, VA. Relation between dietary fat intake type and serum fatty acid status in children with cystic fibrosis. *J Pediatr Gastroenterol Nutr* 55, 605-611 (2012).
335. Al-Turkmani, MR, Freedman, SD & Laposata, M. Fatty acid alterations and n-3 fatty acid supplementation in cystic fibrosis. *Prostaglandins Leukot Essent Fatty Acids* 77, 309-318 (2007).
336. Coste, TC, Armand, M, Lebacqz, J, Lebecque, P, Wallemacq, P & Leal, T. An overview of monitoring and supplementation of omega 3 fatty acids in cystic fibrosis. *Clin Biochem* 40, 511-520 (2007).
337. Kuo, PT, Huang, NN & Bassett, DR. The fatty acid composition of the serum chylomicrons and adipose tissue of children with cystic fibrosis of the pancreas. *J Pediatr* 60, 394-403 (1962).
338. Seegmiller, AC. Abnormal unsaturated fatty acid metabolism in cystic fibrosis: biochemical mechanisms and clinical implications. *Int J Mol Sci* 15, 16083-16099 (2014).
339. Cawood, AL, Carroll, MP, Wootton, SA & Calder, PC. Is there a case for n-3 fatty acid supplementation in cystic fibrosis? *Curr Opin Clin Nutr Metab Care* 8, 153-159 (2005).
340. Craig-Schmidt, MC, Faircloth, SA, Teer, PA, Weete, JD & Wu, CY. The essential fatty acid deficient chicken as a model for cystic fibrosis. *Am J Clin Nutr* 44, 816-824 (1986).
341. Harper, TB, Chase, HP, Henson, J & Henson, PM. Essential fatty acid deficiency in the rabbit as a model of nutritional impairment in cystic fibrosis. In vitro and in vivo effects on lung defense mechanisms. *Am Rev Respir Dis* 126, 540-547 (1982).
342. Goodgame, JT, Lowry, SF & Brennan, MF. Essential fatty acid deficiency in total parenteral nutrition: time course of development and suggestions for therapy. *Surgery* 84, 271-277 (1978).
343. Holman, RT, Johnson, SB & Hatch, TF. A case of human linolenic acid deficiency involving neurological abnormalities. *Am J Clin Nutr* 35, 617-623 (1982).
344. Jeppesen, PB, Hoy, CE & Mortensen, PB. Deficiencies of essential fatty acids, vitamin A and E and changes in plasma lipoproteins in patients with reduced fat absorption or intestinal failure. *Eur J Clin Nutr* 54, 632-642 (2000).
345. Mascioli, EA, Lopes, SM, Champagne, C & Driscoll, DF. Essential fatty acid deficiency and home total parenteral nutrition patients. *Nutrition* 12, 245-249 (1996).
346. O'Neill, JA, Jr., Caldwell, MD & Meng, HC. Essential fatty acid deficiency in surgical patients. *Ann Surg* 185, 535-542 (1977).
347. Shaw, V & Lawson, M. *Clinical Paediatric Dietetics*, (Blackwell Publishing, 2001).
348. Shoff, SM, Ahn, HY, Davis, L & Lai, H. Temporal associations among energy intake, plasma linoleic acid, and growth improvement in response to treatment initiation after diagnosis of cystic fibrosis. *Pediatrics* 117, 391-400 (2006).
349. Oliveira, G, Dorado, A, Oliveira, C, Padilla, A, Rojo-Martinez, G, Garcia-Escobar, E, *et al.* Serum phospholipid fatty acid profile and dietary intake in an adult Mediterranean population with cystic fibrosis. *Br J Nutr* 96, 343-349 (2006).
350. Oliveira, G, Oliveira, C, Casado-Miranda, E, Padilla, A, Dorado, A, Rojo-Martinez, G, *et al.* Markers for the validation of reported dietary intake in adults with cystic fibrosis. *J Am Diet Assoc* 109, 1704-1711 (2009).
351. National Heart Foundation of Australia. Omega 3 fatty acid: The importance of fat in a healthy diet. (National Heart Foundation of Australia, Australia, 2015). <https://www.heartfoundation.org.au/news/omega-3-fatty-acid-the-importance-of-fat-in-a-healthy-diet>
352. Barber, MD & Fearon, KC. Tolerance and incorporation of a high-dose eicosapentaenoic acid diester emulsion by patients with pancreatic cancer cachexia. *Lipids* 36, 347-351 (2001).
353. Henderson, WR, Jr., Astley, SJ, McCready, MM, Kushmerick, P, Casey, S, Becker, JW, *et al.* Oral absorption of omega-3 fatty acids in patients with cystic fibrosis who have pancreatic insufficiency and in healthy control subjects. *J Pediatr* 124, 400-408 (1994).
354. Lawrence, R & Sorrell, T. Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4. *Lancet* 342, 465-469 (1993).
355. Keen, C, Olin, AC, Eriksson, S, Ekman, A, Lindblad, A, Basu, S, *et al.* Supplementation with fatty acids influences the airway nitric oxide and inflammatory markers in patients with cystic fibrosis. *J Pediatr Gastroenterol Nutr* 50, 537-544 (2010).
356. Ciofu, O & Lykkesfeldt, J. Antioxidant supplementation for lung disease in cystic fibrosis. *Cochrane Database Syst Rev* 8, Cd007020 (2014).

357. Okebukola, PO, Kansra, S & Barrett, J. Vitamin E supplementation in people with cystic fibrosis. *Cochrane Database Syst Rev*, Cd009422 (2014).
358. Bonifant, CM, Shevill, E & Chang, AB. Vitamin A supplementation for cystic fibrosis. *Cochrane Database Syst Rev*, Cd006751 (2014).
359. Maqbool, A & Stallings, VA. Update on fat-soluble vitamins in cystic fibrosis. *Curr Opin Pulm Med* 14, 574-581 (2008).
360. Jagannath, VA, Fedorowicz, Z, Thaker, V & Chang, AB. Vitamin K supplementation for cystic fibrosis. *Cochrane Database Syst Rev* 1, Cd008482 (2015).
361. MIMS Online. Vitamin A, Vitamin D, Vitamin E, Vitamin K. (MIMS, Australia, 2016). <http://www.mims.com.au/index.php/products/mims-online>
362. Cantin, AM, White, TB, Cross, CE, Forman, HJ, Sokol, RJ & Borowitz, D. Antioxidants in cystic fibrosis. Conclusions from the CF antioxidant workshop, Bethesda, Maryland, November 11-12, 2003. *Free Radic Biol Med* 42, 15-31 (2007).
363. Sathe, MN & Patel, AS. Update in pediatrics: focus on fat-soluble vitamins. *Nutr Clin Pract* 25, 340-346 (2010).
364. Galli, F, Battistoni, A, Gambari, R, Pompella, A, Bragonzi, A, Pilolli, F, *et al.* Oxidative stress and antioxidant therapy in cystic fibrosis. *Biochim Biophys Acta* 1822, 690-713 (2012).
365. Morton, A. Why bother to take vitamins? *J R Soc Med* 104 Suppl 1, S19-29 (2011).
366. Cobanoglu, N, Ozcelik, U, Gocmen, A, Kiper, N & Dogru, D. Antioxidant effect of beta-carotene in cystic fibrosis and bronchiectasis: clinical and laboratory parameters of a pilot study. *Acta Paediatr* 91, 793-798 (2002).
367. Back, EI, Frindt, C, Nohr, D, Frank, J, Ziebach, R, Stern, M, *et al.* Antioxidant deficiency in cystic fibrosis: when is the right time to take action? *Am J Clin Nutr* 80, 374-384 (2004).
368. Lagrange-Puget, M, Durieu, I, Ecochard, R, Abbas-Chorfa, F, Draï, J, Steghens, JP, *et al.* Longitudinal study of oxidative status in 312 cystic fibrosis patients in stable state and during bronchial exacerbation. *Pediatr Pulmonol* 38, 43-49 (2004).
369. Papas, KA, Sontag, MK, Pardee, C, Sokol, RJ, Sagel, SD, Accurso, FJ, *et al.* A pilot study on the safety and efficacy of a novel antioxidant rich formulation in patients with cystic fibrosis. *J Cyst Fibros* 7, 60-67 (2008).
370. Aird, FK, Greene, SA, Ogston, SA, Macdonald, TM & Mukhopadhyay, S. Vitamin A and lung function in CF. *J Cyst Fibros* 5, 129-131 (2006).
371. Roddy, MF, Grealley, P, Clancy, G, Leen, G, Feehan, S & Elnazir, B. Night blindness in a teenager with cystic fibrosis. *Nutr Clin Pract* 26, 718-721 (2011).
372. Tinley, CG, Withers, NJ, Sheldon, CD, Quinn, AG & Jackson, AA. Zinc therapy for night blindness in cystic fibrosis. *J Cyst Fibros* 7, 333-335 (2008).
373. Joshi, D, Dhawan, A, Baker, AJ & Heneghan, MA. An atypical presentation of cystic fibrosis: a case report. *J Med Case Rep* 2, 201 (2008).
374. Matel, JL. Nutritional management of cystic fibrosis. *JPEN J Parenter Enteral Nutr* 36, 60s-67s (2012).
375. Myhre, AM, Carlsen, MH, Bohn, SK, Wold, HL, Laake, P & Blomhoff, R. Water-miscible, emulsified, and solid forms of retinol supplements are more toxic than oil-based preparations. *Am J Clin Nutr* 78, 1152-1159 (2003).
376. Food Standards Australia and New Zealand. NUTTAB 2010. (Food Standards Australia New Zealand, 2015). <http://www.foodstandards.gov.au/science/monitoringnutrients/nutrientables/Pages/default.aspx>
377. Pazirandah, S & Burns, D. Overview of Vitamin A. (UpToDate.com, USA, 2014). <http://www.uptodate.com/contents/overview-of-vitamin-a>
378. Feranchak, AP, Gralla, J, King, R, Ramirez, RO, Corkill, M, Narkewicz, MR, *et al.* Comparison of indices of vitamin A status in children with chronic liver disease. *Hepatology* 42, 782-792 (2005).
379. de Pee, S & Dary, O. Biochemical indicators of vitamin A deficiency: serum retinol and serum retinol binding protein. *J Nutr* 132, 2895s-2901s (2002).
380. Greaves, RF, Woollard, GA, Hoad, KE, Walmsley, TA, Johnson, LA, Briscoe, S, *et al.* Laboratory medicine best practice guideline: vitamins A, E and the carotenoids in blood. *Clin Biochem Rev* 35, 81-113 (2014).
381. Feranchak, AP & Sokol, RJ. *Liver Disease in Children: Medical and nutritional management of cholestasis in infants and children*, (Cambridge University Press, New York, 2007).
382. Holick, MF, Binkley, NC, Bischoff-Ferrari, HA, Gordon, CM, Hanley, DA, Heaney, RP, *et al.* Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab* 96, 1911-1930 (2011).
383. Smith, BA, Cogswell, A & Garcia, G. Vitamin D and depressive symptoms in children with cystic fibrosis. *Psychosomatics* 55, 76-81 (2014).
384. Pincikova, T, Nilsson, K, Moen, IE, Fluge, G, Hollsing, A, Knudsen, PK, *et al.* Vitamin D deficiency as a risk factor for cystic fibrosis-related diabetes in the Scandinavian Cystic Fibrosis Nutritional Study. *Diabetologia* 54, 3007-3015 (2011).
385. Rathish, N & Maseh, A. Vitamin D: the "sunshine" Vitamin. *Journal of Pharmacology and Pharmacotherapeutics* 3, 118-126 (2012).
386. Kelly, A & Ren, CL. Is vitamin D deficiency the root of all pulmonary evils? *Ann Am Thorac Soc* 11, 220-222 (2014).
387. Ebeling, PR, Daly, RM, Kerr, DA & Kimlin, MG. Building healthy bones throughout life: an evidence-informed strategy to prevent osteoporosis in Australia. *Med J Aust* 199, S1 (2013).



388. Schlingmann, KP, Kaufmann, M, Weber, S, Irwin, A, Goos, C, John, U, *et al.* Mutations in CYP24A1 and idiopathic infantile hypercalcemia. *N Engl J Med* 365, 410-421 (2011).
389. Jones, G. Pharmacokinetics of vitamin D toxicity. *Am J Clin Nutr* 88, 582s-586s (2008).
390. Vogiatzi, MG, Jacobson-Dickman, E & DeBoer, MD. Vitamin D supplementation and risk of toxicity in pediatrics: a review of current literature. *J Clin Endocrinol Metab* 99, 1132-1141 (2014).
391. Aris, RM, Merkel, PA, Bachrach, LK, Borowitz, DS, Boyle, MP, Elkin, SL, *et al.* Guide to bone health and disease in cystic fibrosis. *J Clin Endocrinol Metab* 90, 1888-1896 (2005).
392. Costa Silva, M & Furlanetto, T. Does serum 25-hydroxyvitamin D decrease during acute-phase response? A systematic review. *Nutrition Research* 35, 91-96 (2015).
393. Pazirandeh, S & Burns, DL. Overview of Vitamin E. Vol. 2016 (UpToDate.com, USA, 2016). <http://www.uptodate.com/contents/overview-of-vitamin-e>
394. Cystic Fibrosis Trust. Standards for the Clinical Care of Children and Adults with Cystic Fibrosis in the UK. (London, United Kingdom, 2011). <https://www.cysticfibrosis.org.uk/the-work-we-do/clinical-care/consensus-documents>
395. Sitrin, MD, Lieberman, F, Jensen, WE, Noronha, A, Milburn, C & Addington, W. Vitamin E deficiency and neurologic disease in adults with cystic fibrosis. *Ann Intern Med* 107, 51-54 (1987).
396. Sokol, RJ, Butler-Simon, N, Heubi, JE, Iannaccone, ST, McClung, HJ, Accurso, F, *et al.* Vitamin E deficiency neuropathy in children with fat malabsorption. Studies in cystic fibrosis and chronic cholestasis. *Ann N Y Acad Sci* 570, 156-169 (1989).
397. Cynamon, HA, Milov, DE, Valenstein, E & Wagner, M. Effect of vitamin E deficiency on neurologic function in patients with cystic fibrosis. *J Pediatr* 113, 637-640 (1988).
398. Wilfond, BS, Farrell, PM, Laxova, A & Mischler, E. Severe hemolytic anemia associated with vitamin E deficiency in infants with cystic fibrosis. Implications for neonatal screening. *Clin Pediatr (Phila)* 33, 2-7 (1994).
399. Sadowska-Woda, I, Rachel, M, Pazdan, J, Bieszczad-Bedrejczuk, E & Pawliszak, K. Nutritional supplement attenuates selected oxidative stress markers in pediatric patients with cystic fibrosis. *Nutr Res* 31, 509-518 (2011).
400. Booth, SL. Roles for vitamin K beyond coagulation. *Annu Rev Nutr* 29, 89-110 (2009).
401. Raederstorff, D, Wyss, A, Calder, PC, Weber, P & Eggersdorfer, M. Vitamin E function and requirements in relation to PUFA. *Br J Nutr* 114, 1113-1122 (2015).
402. Thurnham, DI, Davies, JA, Crump, BJ, Situnayake, RD & Davis, M. The use of different lipids to express serum tocopherol: lipid ratios for the measurement of vitamin E status. *Ann Clin Biochem* 23 ( Pt 5), 514-520 (1986).
403. Baker, RD, Coburn-Miller, C & Baker, SS. Cystic Fibrosis: Nutritional issues. Vol. 2014 (eds. Motil, K.J., Mallory, G.B. & Heyman, M.B.) (Up to Date, 2014).
404. Rhodes, B, Nash, EF, Tullis, E, Pencharz, PB, Brotherwood, M, Dupuis, A, *et al.* Prevalence of dyslipidemia in adults with cystic fibrosis. *J Cyst Fibros* 9, 24-28 (2010).
405. Hathcock, JN, Azzi, A, Blumberg, J, Bray, T, Dickinson, A, Frei, B, *et al.* Vitamins E and C are safe across a broad range of intakes. *Am J Clin Nutr* 81, 736-745 (2005).
406. Klein, EA, Thompson, IM, Jr., Tangen, CM, Crowley, JJ, Lucia, MS, Goodman, PJ, *et al.* Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). *Jama* 306, 1549-1556 (2011).
407. Harshman, SG, Saltzman, E & Booth, SL. Vitamin K: dietary intake and requirements in different clinical conditions. *Curr Opin Clin Nutr Metab Care* 17, 531-538 (2014).
408. Conway, SP. Vitamin K in cystic fibrosis. *J R Soc Med* 97 Suppl 44, 48-51 (2004).
409. Institute of Medicine (US) Panel on Micronutrients. Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc. (National Academies Press (US), Washington (DC), 2001). <http://www.ncbi.nlm.nih.gov/books/NBK222310/>
410. United States Department of Agriculture. USDA National nutrient database for standard reference. (United States Department of Agriculture, Agricultural Research Service, USA, 2015). <https://ndb.nal.usda.gov/ndb/>
411. UK Cystic Fibrosis Trust Nutrition Working Group. Nutritional Management of Cystic Fibrosis. (Cystic Fibrosis Trust, United Kingdom, 2016). <https://www.cysticfibrosis.org.uk/the-work-we-do/clinical-care/consensus-documents>
412. Fischer, R, Simmerlein, R, Huber, RM, Schiffli, H & Lang, SM. Lung disease severity, chronic inflammation, iron deficiency, and erythropoietin response in adults with cystic fibrosis. *Pediatr Pulmonol* 42, 1193-1197 (2007).
413. O'Connor T, M, McGrath, DS, Short, C, O'Donnell M, J, Sheehy, M & Bredin, CP. Subclinical anaemia of chronic disease in adult patients with cystic fibrosis. *J Cyst Fibros* 1, 31-34 (2002).
414. Pond, MN, Morton, AM & Conway, SP. Functional iron deficiency in adults with cystic fibrosis. *Respir Med* 90, 409-413 (1996).
415. Uijterschout, L, Nuijsink, M, Hendriks, D, Vos, R & Brus, F. Iron deficiency occurs frequently in children with cystic fibrosis. *Pediatr Pulmonol* 49, 458-462 (2014).
416. Iron Disorders Institute. Iron deficiency anaemia. (Iron Disorders Institute, USA, 2009). <http://www.irondisorders.org/iron-deficiency-anemia>

417. Thomas, DW, Hinchliffe, RF, Briggs, C, Macdougall, IC, Littlewood, T & Cavill, I. Guideline for the laboratory diagnosis of functional iron deficiency. *Br J Haematol* 161, 639-648 (2013).
418. Pasricha, SR, Flecknoe-Brown, SC, Allen, KJ, Gibson, PR, McMahon, LP, Olynyk, JK, *et al.* Diagnosis and management of iron deficiency anaemia: a clinical update. *Med J Aust* 193, 525-532 (2010).
419. Ehrhardt, P, Miller, MG & Littlewood, JM. Iron deficiency in cystic fibrosis. *Arch Dis Child* 62, 185-187 (1987).
420. Reid, DW, Withers, NJ, Francis, L, Wilson, JW & Kotsimbos, TC. Iron deficiency in cystic fibrosis: relationship to lung disease severity and chronic *Pseudomonas aeruginosa* infection. *Chest* 121, 48-54 (2002).
421. Neilands, JB. Siderophores: structure and function of microbial iron transport compounds. *J Biol Chem* 270, 26723-26726 (1995).
422. Ater, JL, Herbst, JJ, Landaw, SA & O'Brien, RT. Relative anemia and iron deficiency in cystic fibrosis. *Pediatrics* 71, 810-814 (1983).
423. National Institute of Health. Iron: Dietary supplement fact sheet. Vol. 2016 (National Institute of Health, Office of Dietary Supplements, USA, 2016). <https://ods.od.nih.gov/factsheets/Iron-HealthProfessional/>
424. Nutrition Australia. Fact sheet: Iron. (Nutrition Australia, Australia, 2014). <http://www.nutritionaustralia.org/national/resource/iron>
425. National Health and Medical Research Council. Eat For Health Infant Feeding Guidelines. (National Health and Medical Research Council and Department of Health and Ageing, Australian Government, 2013). <https://www.nhmrc.gov.au/guidelines-publications/n56?>
426. Lynch, S. The rationale for selecting and standardizing iron status indicators. In: World Health Organisation. Report: Priorities in the assessment of vitamin A and iron status in populations, Panama City, Panama, 15 - 17 September 2010. (World Health Organisation, Geneva, 2012). [http://www.who.int/nutrition/publications/micronutrients/background\\_paper3\\_report\\_assessment\\_vitAandiron\\_status.pdf](http://www.who.int/nutrition/publications/micronutrients/background_paper3_report_assessment_vitAandiron_status.pdf)
427. Zhu, A, Kaneshiro, M & Kaunitz, JD. Evaluation and treatment of iron deficiency anemia: a gastroenterological perspective. *Dig Dis Sci* 55, 548-559 (2010).
428. Jahnhen-Dechent, W & Ketteler, M. Magnesium basics. *Clin Kidney J* 5, i3-i14 (2012).
429. Gupta, A, Eastham, KM, Wrightson, N & Spencer, DA. Hypomagnesaemia in cystic fibrosis patients referred for lung transplant assessment. *J Cyst Fibros* 6, 360-362 (2007).
430. Kelleher, J, Goode, HF, Field, HP, Walker, BE, Miller, MG & Littlewood, JM. Essential element nutritional status in cystic fibrosis. *Hum Nutr Appl Nutr* 40, 79-84 (1986).
431. Foucard, T, Gebre-Medhin, M, Gustavson, KH & Lindh, U. Low concentrations of sodium and magnesium in erythrocytes from cystic fibrosis heterozygotes. *Acta Paediatr Scand* 80, 57-61 (1991).
432. Swaminathan, R. Magnesium metabolism and its disorders. *Clin Biochem Rev* 24, 47-66 (2003).
433. Martin, HE. Clinical magnesium deficiency. *Ann N Y Acad Sci* 162, 891-900 (1969).
434. Booth, CC, Babouris, N, Hanna, S & Macintyre, I. Incidence of hypomagnesaemia in intestinal malabsorption. *Br Med J* 2, 141-144 (1963).
435. Foodworks. Magnesium containing foods. (Xyris, Australia, 2012 - 2016). <https://www.xyris.com.au/>
436. Saris, NE, Mervaala, E, Karppanen, H, Khawaja, JA & Lewenstam, A. Magnesium. An update on physiological, clinical and analytical aspects. *Clin Chim Acta* 294, 1-26 (2000).
437. Arnaud, MJ. Update on the assessment of magnesium status. *Br J Nutr* 99 Suppl 3, S24-36 (2008).
438. UK Cystic Fibrosis Trust Bone Mineralisation Working Group. Bone mineralisation in Cystic Fibrosis. (Cystic Fibrosis Trust, United Kingdom, 2007).
439. Emkey, RD & Emkey, GR. Calcium metabolism and correcting calcium deficiencies. *Endocrinol Metab Clin North Am* 41, 527-556 (2012).
440. Lanham-New, SA. Importance of calcium, vitamin D and vitamin K for osteoporosis prevention and treatment. *Proc Nutr Soc* 67, 163-176 (2008).
441. Sermet-Gaudelus, I, Castanet, M, Retsch-Bogart, G & Aris, RM. Update on cystic fibrosis-related bone disease: a special focus on children. *Paediatr Respir Rev* 10, 134-142 (2009).
442. Bianchi, ML, Colombo, C, Assael, BM, Dubini, A, Lombardo, M, Quattrucci, S, *et al.* Treatment of low bone density in young people with cystic fibrosis: a multicentre, prospective, open-label observational study of calcium and calcifediol followed by a randomised placebo-controlled trial of alendronate. *Lancet Respir Med* 1, 377-385 (2013).
443. Schulze, KJ, O'Brien, KO, Germain-Lee, EL, Baer, DJ, Leonard, A & Rosenstein, BJ. Efficiency of calcium absorption is not compromised in clinically stable prepubertal and pubertal girls with cystic fibrosis. *Am J Clin Nutr* 78, 110-116 (2003).
444. Moran, A. Endocrine complications of cystic fibrosis. *Adolesc Med* 13, 145-159, vii-viii (2002).
445. Conway, SP, Oldroyd, B, Brownlee, KG, Wolfe, SP & Truscott, JG. A cross-sectional study of bone mineral density in children and adolescents attending a Cystic Fibrosis Centre. *J Cyst Fibros* 7, 469-476 (2008).
446. Schulze, KJ, O'Brien, K, O, Germain-Lee, EL, Baer, DJ, Leonard, AL & Rosenstein, BJ. Endogenous fecal losses of calcium compromise calcium balance in pancreatic-insufficient girls with cystic fibrosis. *J Pediatr* 143, 765-771 (2003).
447. Cashman, KD. Calcium intake, calcium bioavailability and bone health. *Br J Nutr* 87 Suppl 2, S169-177 (2002).





448. Legris, GJ, Dearborn, D, Stern, RC, Geiss, CL, Hopfer, U, Douglas, JG, *et al.* Sodium space and intravascular volume: dietary sodium effects in cystic fibrosis and healthy adolescent subjects. *Pediatrics* 101, 48-56 (1998).
449. Wheatley, CM, Wilkins, BW & Snyder, EM. Exercise is medicine in cystic fibrosis. *Exerc Sport Sci Rev* 39, 155-160 (2011).
450. Bar-Or, O, Blimkie, CJ, Hay, JA, MacDougall, JD, Ward, DS & Wilson, WM. Voluntary dehydration and heat intolerance in cystic fibrosis. *Lancet* 339, 696-699 (1992).
451. Emrich, HM, Stoll, E, Friolet, B, Colombo, JP, Richterich, R & Rossi, E. Sweat composition in relation to rate of sweating in patients with cystic fibrosis of the pancreas. *Pediatr Res* 2, 464-478 (1968).
452. Ozcelik, U, Gocmen, A, Kiper, N, Coskun, T, Yilmaz, E & Ozcug, M. Sodium chloride deficiency in cystic fibrosis patients. *Eur J Pediatr* 153, 829-831 (1994).
453. Blair, M, Frazer, C & Gaskin, KJ. *The Feeding Guide: A handbook on the nutritional composition of infant formula, enteral & supplementary feeds.*, (The Children's Hospital Westmead, Westmead, N.S.W. James Fairfax Institute of Paediatric Nutrition, The Children's Hospital at Westmead,, 2014).
454. Morton, A. An unusual cause of exercise-induced hyponatremia. *Emerg Med Australas* 19, 377-378 (2007).
455. Smith, HR, Dhatt, GS, Melia, WM & Dickinson, JG. Cystic fibrosis presenting as hyponatraemic heat exhaustion. *Bmj* 310, 579-580 (1995).
456. Kaskavage, J & Sklansky, D. Hyponatremia-associated rhabdomyolysis following exercise in an adolescent with cystic fibrosis. *Pediatrics* 130, e220-223 (2012).
457. Manz, F. Hydration and disease. *J Am Coll Nutr* 26, 535s-541s (2007).
458. Sawka, MN, Burke, LM, Eichner, ER, Maughan, RJ, Montain, SJ & Stachenfeld, NS. American College of Sports Medicine position stand. Exercise and fluid replacement. *Med Sci Sports Exerc* 39, 377-390 (2007).
459. Russo, MA, Hogenauer, C, Coates, SW, Jr., Santa Ana, CA, Porter, JL, Rosenblatt, RL, *et al.* Abnormal passive chloride absorption in cystic fibrosis jejenum functionally opposes the classic chloride secretory defect. *J Clin Invest* 112, 118-125 (2003).
460. Schindler, T, Michel, S & Wilson, AW. Nutrition Management of Cystic Fibrosis in the 21st Century. *Nutr Clin Pract* 30, 488-500 (2015).
461. Foodworks. Sodium containing foods. (Xyris, Australia, 2012 - 2016). <https://www.xyris.com.au/>
462. Rangan, AM & Samman, S. Zinc intake and its dietary sources: results of the 2007 Australian National Children's Nutrition and Physical Activity Survey. *Nutrients* 4, 611-624 (2012).
463. Corbo, MD & Lam, J. Zinc deficiency and its management in the pediatric population: a literature review and proposed etiologic classification. *J Am Acad Dermatol* 69, 616-624.e611 (2013).
464. Livingstone, C. Zinc: physiology, deficiency, and parenteral nutrition. *Nutr Clin Pract* 30, 371-382 (2015).
465. Krebs, NF. Update on zinc deficiency and excess in clinical pediatric practice. *Ann Nutr Metab* 62 Suppl 1, 19-29 (2013).
466. Gibson, R & Heath, AL. Population groups at risk of zinc deficiency in Australia and New Zealand. *Nutrition & Dietetics* 68, 97 - 108 (2011).
467. Krebs, NF, Sontag, M, Accurso, FJ & Hambidge, KM. Low plasma zinc concentrations in young infants with cystic fibrosis. *J Pediatr* 133, 761-764 (1998).
468. Easley, D, Krebs, N, Jefferson, M, Miller, L, Erskine, J, Accurso, F, *et al.* Effect of pancreatic enzymes on zinc absorption in cystic fibrosis. *J Pediatr Gastroenterol Nutr* 26, 136-139 (1998).
469. Krebs, NF, Westcott, JE, Arnold, TD, Kluger, BM, Accurso, FJ, Miller, LV, *et al.* Abnormalities in zinc homeostasis in young infants with cystic fibrosis. *Pediatr Res* 48, 256-261 (2000).
470. Peroni, DG, Banzato, C, Guerresi, S, Schena, D, Deganello, M, Boner, AL, *et al.* Severe refractory dermatitis and cystic fibrosis. *Arch Dis Child* 97, 205 (2012).
471. Crone, J, Huber, WD, Eichler, I & Granditsch, G. Acrodermatitis enteropathica-like eruption as the presenting sign of cystic fibrosis--case report and review of the literature. *Eur J Pediatr* 161, 475-478 (2002).
472. Sharma, D, Farahbakhsh, N, Sharma, P & Shastri, S. Role of oral zinc supplementation for reduction of neonatal hyperbilirubinemia: a systematic review of current evidence. *J Matern Fetal Neonatal Med*, 1-10 (2016).
473. King, JC, Brown, KH, Gibson, RS, Krebs, NF, Lowe, NM, Siekmann, JH, *et al.* Biomarkers of Nutrition for Development (BOND)-Zinc Review. *J Nutr* (2016).
474. Foodworks. Zinc containing foods. (Xyris, Australia, 2012 - 2016). <https://www.xyris.com.au/>
475. Thane, CW, Bates, CJ & Prentice, A. Zinc and vitamin A intake and status in a national sample of British young people aged 4-18 y. *Eur J Clin Nutr* 58, 363-375 (2004).
476. Ansari, EA, Sahni, K, Etherington, C, Morton, A, Conway, SP, Moya, E, *et al.* Ocular signs and symptoms and vitamin A status in patients with cystic fibrosis treated with daily vitamin A supplements. *Br J Ophthalmol* 83, 688-691 (1999).
477. Brown, KH, Peerson, JM, Rivera, J & Allen, LH. Effect of supplemental zinc on the growth and serum zinc concentrations of prepubertal children: a meta-analysis of randomized controlled trials. *Am J Clin Nutr* 75, 1062-1071 (2002).
478. Berry, AJ. Pancreatic enzyme replacement therapy during pancreatic insufficiency. *Nutr Clin Pract* 29, 312-321 (2014).

479. Anthony, H, Collins, CE, Davidson, G, Mews, C, Robinson, P, Shepherd, R, *et al.* Pancreatic enzyme replacement therapy in cystic fibrosis: Australian guidelines. Pediatric Gastroenterological Society and the Dietitians Association of Australia. *J Paediatr Child Health* 35, 125-129 (1999).
480. Layer, P, Go, VL & DiMagno, EP. Fate of pancreatic enzymes during small intestinal aboral transit in humans. *Am J Physiol* 251, G475-480 (1986).
481. Borowitz, D, Stevens, C, Brettman, LR, Campion, M, Chatfield, B, Cipolli, M, *et al.* International phase III trial of liprotamase efficacy and safety in pancreatic-insufficient cystic fibrosis patients. *J Cyst Fibros* 10, 443-452 (2011).
482. Atkinson, SN. A comparative study of the enzyme activity, acid resistance and dissolution characteristics of four enteric coated microsphere preparations of pancreatin. *Eur J Clin Res* 1, 37-45 (1991).
483. Stapleton, D, Anthony, H., Collins, C., Powell, E., King, S. & Mews, C. Clinical practice guidelines: implementing the Australian pancreatic enzyme replacement therapy guidelines for cystic fibrosis. *Australian Journal of Nutrition and Dietetics* 56, 91-96 (1999).
484. Kopelman, H, Durie, P, Gaskin, K, Weizman, Z & Forstner, G. Pancreatic fluid secretion and protein hyperconcentration in cystic fibrosis. *N Engl J Med* 312, 329-334 (1985).
485. Lindkvist, B, Phillips, ME & Dominguez-Munoz, JE. Clinical, anthropometric and laboratory nutritional markers of pancreatic exocrine insufficiency: Prevalence and diagnostic use. *Pancreatology* 15, 589-597 (2015).
486. Wouthuyzen-Bakker, M, Bodewes, FA & Verkade, HJ. Persistent fat malabsorption in cystic fibrosis; lessons from patients and mice. *J Cyst Fibros* 10, 150-158 (2011).
487. Kristidis, P, Bozon, D, Corey, M, Markiewicz, D, Rommens, J, Tsui, LC, *et al.* Genetic determination of exocrine pancreatic function in cystic fibrosis. *Am J Hum Genet* 50, 1178-1184 (1992).
488. Couper, RT, Corey, M, Moore, DJ, Fisher, LJ, Forstner, GG & Durie, PR. Decline of exocrine pancreatic function in cystic fibrosis patients with pancreatic sufficiency. *Pediatr Res* 32, 179-182 (1992).
489. Waters, DL, Dorney, SF, Gaskin, KJ, Gruca, MA, O'Halloran, M & Wilcken, B. Pancreatic function in infants identified as having cystic fibrosis in a neonatal screening program. *N Engl J Med* 322, 303-308 (1990).
490. O'Sullivan, BP, Baker, D, Leung, KG, Reed, G, Baker, SS & Borowitz, D. Evolution of pancreatic function during the first year in infants with cystic fibrosis. *J Pediatr* 162, 808-812 e801 (2013).
491. Forsmark, CE. Management of chronic pancreatitis. *Gastroenterology* 144, 1282-1291 e1283 (2013).
492. Ooi, CY & Durie, PR. Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in pancreatitis. *J Cyst Fibros* 11, 355-362 (2012).
493. Hellmig, S, Von Schoning, F, Gadow, C, Katsoulis, S, Hedderich, J, Folsch, UR, *et al.* Gastric emptying time of fluids and solids in healthy subjects determined by <sup>13</sup>C breath tests: influence of age, sex and body mass index. *J Gastroenterol Hepatol* 21, 1832-1838 (2006).
494. Fieker, A, Philpott, J & Armand, M. Enzyme replacement therapy for pancreatic insufficiency: present and future. *Clin Exp Gastroenterol* 4, 55-73 (2011).
495. Collins, CE, Francis, JL, Thomas, P, Henry, RL & O'Loughlin, EV. Gastric emptying time is faster in cystic fibrosis. *J Pediatr Gastroenterol Nutr* 25, 492-498 (1997).
496. Roulet, M, Weber, AM, Paradis, Y, Roy, CC, Chartrand, L, Lasalle, R, *et al.* Gastric emptying and lingual lipase activity in cystic fibrosis. *Pediatr Res* 14, 1360-1362 (1980).
497. Cucchiara, S, Raia, V, Minella, R, Frezza, T, De Vizia, B & De Ritis, G. Ultrasound measurement of gastric emptying time in patients with cystic fibrosis and effect of ranitidine on delayed gastric emptying. *J Pediatr* 128, 485-488 (1996).
498. Working Party of the Australasian Pancreatic Club, Smith, RC, Smith, SF, Wilson, J, Pearce, C, Wray, N, *et al.* Summary and recommendations from the Australasian guidelines for the management of pancreatic exocrine insufficiency. *Pancreatology* (2015).
499. Hayakawa, T, Kondo, T, Shibata, T, Noda, A, Suzuki, T & Nakano, S. Relationship between pancreatic exocrine function and histological changes in chronic pancreatitis. *Am J Gastroenterol* 87, 1170-1174 (1992).
500. Schibli, S, Corey, M, Gaskin, KJ, Ellis, L & Durie, PR. Towards the ideal quantitative pancreatic function test: analysis of test variables that influence validity. *Clin Gastroenterol Hepatol* 4, 90-97 (2006).
501. van de Kamer, JH, Bokkel Huinink, H & Weyers, HA. Rapid method for the determination of fat in feces. *J Biol Chem* 177, 347-355 (1949).
502. Thompson, JB, Su, CK, Ringrose, RE & Welsh, JD. Fecal triglycerides. II. Digestive versus absorptive steatorrhea. *J Lab Clin Med* 73, 521-530 (1969).
503. Fomon, SJ, Ziegler, EE, Thomas, LN, Jensen, RL & Filer, LJ, Jr. Excretion of fat by normal full-term infants fed various milks and formulas. *Am J Clin Nutr* 23, 1299-1313 (1970).
504. Roberts, IM, Poturich, C & Wald, A. Utility of fecal fat concentrations as screening test in pancreatic insufficiency. *Dig Dis Sci* 31, 1021-1024 (1986).
505. Gullo, L, Graziano, L, Babbini, S, Battistini, A, Lazzari, R & Pezzilli, R. Faecal elastase 1 in children with cystic fibrosis. *Eur J Pediatr* 156, 770-772 (1997).
506. Glasbrenner, B, Schon, A, Klatt, S, Beckh, K & Adler, G. Clinical evaluation of the faecal elastase test in the diagnosis and staging of chronic pancreatitis. *Eur J Gastroenterol Hepatol* 8, 1117-1120 (1996).



507. Keim, V, Teich, N & Moessner, J. Clinical value of a new fecal elastase test for detection of chronic pancreatitis. *Clin Lab* 49, 209-215 (2003).
508. Girella, E, Faggionato, P, Benetazzo, D & Mastella, G. The assay of chymotrypsin in stool as a simple and effective test of exocrine pancreatic activity in cystic fibrosis. *Pancreas* 3, 254-262 (1988).
509. Dominguez-Munoz, JE, Hieronymus, C, Sauerbruch, T & Malfertheiner, P. Fecal elastase test: evaluation of a new noninvasive pancreatic function test. *Am J Gastroenterol* 90, 1834-1837 (1995).
510. Colombo, C, Maiavacca, R, Ronchi, M, Consalvo, E, Amoretti, M & Giunta, A. The steatocrit: a simple method for monitoring fat malabsorption in patients with cystic fibrosis. *J Pediatr Gastroenterol Nutr* 6, 926-930 (1987).
511. Amann, ST, Josephson, SA & Toskes, PP. Acid steatocrit: a simple, rapid gravimetric method to determine steatorrhea. *Am J Gastroenterol* 92, 2280-2284 (1997).
512. Ghos, YF, Vantrappen, GR, Rutgeerts, PJ & Schurmans, PC. A mixed-triglyceride breath test for intraluminal fat digestive activity. *Digestion* 22, 239-247 (1981).
513. Vantrappen, GR, Rutgeerts, PJ, Ghos, YF & Hiele, MI. Mixed triglyceride breath test: a noninvasive test of pancreatic lipase activity in the duodenum. *Gastroenterology* 96, 1126-1134 (1989).
514. Couper, RT, Corey, M, Durie, PR, Forstner, GG & Moore, DJ. Longitudinal evaluation of serum trypsinogen measurement in pancreatic-insufficient and pancreatic-sufficient patients with cystic fibrosis. *J Pediatr* 127, 408-413 (1995).
515. Costantini, D, Padoan, R, Curcio, L & Giunta, A. The management of enzymatic therapy in cystic fibrosis patients by an individualized approach. *J Pediatr Gastroenterol Nutr* 7 Suppl 1, S36-39 (1988).
516. Borowitz, DS, Grand, RJ & Durie, PR. Use of pancreatic enzyme supplements for patients with cystic fibrosis in the context of fibrosing colonopathy. Consensus Committee. *J Pediatr* 127, 681-684 (1995).
517. Freiman, JP & FitzSimmons, SC. Colonic strictures in patients with cystic fibrosis: results of a survey of 114 cystic fibrosis care centers in the United States. *J Pediatr Gastroenterol Nutr* 22, 153-156 (1996).
518. FitzSimmons, SC, Burkhart, GA, Borowitz, D, Grand, RJ, Hammerstrom, T, Durie, PR, *et al.* High-dose pancreatic-enzyme supplements and fibrosing colonopathy in children with cystic fibrosis. *N Engl J Med* 336, 1283-1289 (1997).
519. Borowitz, D, Gelfond, D, Maguiness, K, Heubi, JE & Ramsey, B. Maximal daily dose of pancreatic enzyme replacement therapy in infants with cystic fibrosis: a reconsideration. *J Cyst Fibros* 12, 784-785 (2013).
520. Ferrie, S, Graham, C & Hoyle, M. Pancreatic enzyme supplementation for patients receiving enteral feeds. *Nutr Clin Pract* 26, 349-351 (2011).
521. Nicolo, M, Stratton, KW, Rooney, W & Boullata, J. Pancreatic enzyme replacement therapy for enterally fed patients with cystic fibrosis. *Nutrition in Clinical Practice* 28, 485-489 (2013).
522. Taylor, CJ, Hillel, PG, Ghosal, S, Frier, M, Senior, S, Tindale, WB, *et al.* Gastric emptying and intestinal transit of pancreatic enzyme supplements in cystic fibrosis. *Arch Dis Child* 80, 149-152 (1999).
523. Boullata, AM & Boullata, JI. Pancreatic enzymes prepared in bicarbonate solution for administration through enteral feeding tubes. *Am J Health Syst Pharm* 72, 1210-1214 (2015).
524. Dutta, SK, Russell, RM & Iber, FL. Impaired acid neutralization in the duodenum in pancreatic insufficiency. *Dig Dis Sci* 24, 775-780 (1979).
525. Borowitz, D, Durie, PR, Clarke, LL, Werlin, SL, Taylor, CJ, Semler, J, *et al.* Gastrointestinal outcomes and confounders in cystic fibrosis. *J Pediatr Gastroenterol Nutr* 41, 273-285 (2005).
526. Robinson, PJ, Smith, AL & Sly, PD. Duodenal pH in cystic fibrosis and its relationship to fat malabsorption. *Dig Dis Sci* 35, 1299-1304 (1990).
527. Gan, KH, Geus, WP, Bakker, W, Lamers, CB & Heijerman, HG. In vitro dissolution profiles of enteric-coated microsphere/microtablet pancreatin preparations at different pH values. *Aliment Pharmacol Ther* 10, 771-775 (1996).
528. Heijerman, HG, Lamers, CB & Bakker, W. Omeprazole enhances the efficacy of pancreatin (pancrease) in cystic fibrosis. *Ann Intern Med* 114, 200-201 (1991).
529. Trapnell, B, Maguiness, KM, Graff, GR, Boyd, D, Caras, SD, Beckmann, K, *et al.* Efficacy and safety of pancrelipase delayed-release capsules in patients with pancreatic insufficiency due to cystic fibrosis. *Gastroenterology* 1, A322 (2009).
530. Davies, JC, Cunningham, S, Harris, WT, Lapey, A, Regelman, WE, Sawicki, GS, *et al.* Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study. *Lancet Respir Med* 4, 107-115 (2016).
531. Cheah, E, Venuti, E, McKay, K & Gaskin, K. ePS05.6 Cessation of pancreatic enzyme replacement therapy (PERT) after initiation of therapy with ivacaftor; a case series. *Journal of Cystic Fibrosis* 14, S51 (2016).
532. Schettler, T. Human exposure to phthalates via consumer products. *Int J Androl* 29, 134-139; discussion 181-135 (2006).
533. Kay, VR, Chambers, C & Foster, WG. Reproductive and developmental effects of phthalate diesters in females. *Crit Rev Toxicol* 43, 200-219 (2013).
534. Swan, SH, Main, KM, Liu, F, Stewart, SL, Kruse, RL, Calafat, AM, *et al.* Decrease in anogenital distance among male infants with prenatal phthalate exposure. *Environ Health Perspect* 113, 1056-1061 (2005).

535. Suzuki, Y, Yoshinaga, J, Mizumoto, Y, Serizawa, S & Shiraishi, H. Foetal exposure to phthalate esters and anogenital distance in male newborns. *Int J Androl* 35, 236-244 (2012).
536. Gallinger, ZR & Nguyen, GC. Presence of phthalates in gastrointestinal medications: is there a hidden danger? *World J Gastroenterol* 19, 7042-7047 (2013).
537. Keller, BO, Davidson, AG & Innis, SM. Phthalate metabolites in urine of CF patients are associated with use of enteric-coated pancreatic enzymes. *Environ Toxicol Pharmacol* 27, 424-427 (2009).
538. Carter, WD. Defining "phthalates". *Environ Health Perspect* 120, A416; author reply A416 (2012).
539. Kelley, KE, Hernandez-Diaz, S, Chaplin, EL, Hauser, R & Mitchell, AA. Identification of phthalates in medications and dietary supplement formulations in the United States and Canada. *Environ Health Perspect* 120, 379-384 (2012).
540. Wilhelm, SM, Rjater, RG & Kale-Pradhan, PB. Perils and pitfalls of long-term effects of proton pump inhibitors. *Expert Rev Clin Pharmacol* 6, 443-451 (2013).
541. Timms, CJ, Yates, DH & Thomas, PS. Diagnosing GOR in Respiratory Medicine. *Front Pharmacol* 2, 40 (2011).
542. Button, BM, Roberts, S, Kotsimbos, TC, Levvey, BJ, Williams, TJ, Bailey, M, *et al.* Gastroesophageal reflux (symptomatic and silent): a potentially significant problem in patients with cystic fibrosis before and after lung transplantation. *J Heart Lung Transplant* 24, 1522-1529 (2005).
543. Pencharz, PB & Durie, PR. Pathogenesis of malnutrition in cystic fibrosis, and its treatment. *Clin Nutr* 19, 387-394 (2000).
544. Dray, X, Kanaan, R, Bienvenu, T, Desmazes-Dufeu, N, Dusser, D, Marteau, P, *et al.* Malnutrition in adults with cystic fibrosis. *Eur J Clin Nutr* 59, 152-154 (2005).
545. Brodzicki, J, Trawinska-Bartnicka, M & Korzon, M. Frequency, consequences and pharmacological treatment of gastroesophageal reflux in children with cystic fibrosis. *Med Sci Monit* 8, Cr529-537 (2002).
546. Bush, A, Bilton, D & Hodson, M. *Hodson and Geddes' Cystic Fibrosis*, (CRC Press, 2015).
547. Pauwels, A, Blondeau, K, Dupont, LJ & Sifrim, D. Mechanisms of increased gastroesophageal reflux in patients with cystic fibrosis. *Am J Gastroenterol* 107, 1346-1353 (2012).
548. Mousa, HM & Woodley, FW. Gastroesophageal reflux in cystic fibrosis: current understandings of mechanisms and management. *Curr Gastroenterol Rep* 14, 226-235 (2012).
549. Pauwels, A, Blondeau, K, Mertens, V, Farre, R, Verbeke, K, Dupont, LJ, *et al.* Gastric emptying and different types of reflux in adult patients with cystic fibrosis. *Aliment Pharmacol Ther* 34, 799-807 (2011).
550. Blondeau, K, Pauwels, A, Dupont, L, Mertens, V, Proesmans, M, Orel, R, *et al.* Characteristics of gastroesophageal reflux and potential risk of gastric content aspiration in children with cystic fibrosis. *J Pediatr Gastroenterol Nutr* 50, 161-166 (2010).
551. Tutuian, R. Adverse effects of drugs on the esophagus. *Best Pract Res Clin Gastroenterol* 24, 91-97 (2010).
552. Palmer, SM, Miralles, AP, Howell, DN, Brazer, SR, Tapson, VF & Davis, RD. Gastroesophageal reflux as a reversible cause of allograft dysfunction after lung transplantation. *Chest* 118, 1214-1217 (2000).
553. Blondeau, K, Dupont, LJ, Mertens, V, Verleden, G, Malfroot, A, Vandenplas, Y, *et al.* Gastro-oesophageal reflux and aspiration of gastric contents in adult patients with cystic fibrosis. *Gut* 57, 1049-1055 (2008).
554. Vandenplas, Y, Rudolph, CD, Di Lorenzo, C, Hassall, E, Liptak, G, Mazur, L, *et al.* Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN). *J Pediatr Gastroenterol Nutr* 49, 498-547 (2009).
555. Hamilton, JW, Boisen, RJ, Yamamoto, DT, Wagner, JL & Reichelderfer, M. Sleeping on a wedge diminishes exposure of the esophagus to refluxed acid. *Dig Dis Sci* 33, 518-522 (1988).
556. Katz, PO, Gerson, LB & Vela, MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. *Am J Gastroenterol* 108, 308-328; quiz 329 (2013).
557. Button, BM, Wilson, C, Dentice, R, Cox, NS, Middleton, A, Tannenbaum, E, *et al.* Physiotherapy for cystic fibrosis in Australia and New Zealand: A clinical practice guideline. *Respirology* 21, 656-667 (2016).
558. Dallemagne, B, Weerts, J, Markiewicz, S, Dewandre, JM, Wahlen, C, Monami, B, *et al.* Clinical results of laparoscopic fundoplication at ten years after surgery. *Surg Endosc* 20, 159-165 (2006).
559. Houwen, RH, van der Doef, HP, Sermet, I, Munck, A, Hauser, B, Walkowiak, J, *et al.* Defining DIOS and constipation in cystic fibrosis with a multicentre study on the incidence, characteristics, and treatment of DIOS. *J Pediatr Gastroenterol Nutr* 50, 38-42 (2010).
560. Colombo, C, Ellemunter, H, Houwen, R, Munck, A, Taylor, C & Wilschanski, M. Guidelines for the diagnosis and management of distal intestinal obstruction syndrome in cystic fibrosis patients. *J Cyst Fibros* 10 Suppl 2, S24-28 (2011).
561. Smith, VV, Schappi, MG, Bisset, WM, Kiparissi, F, Jaffe, A, Milla, PJ, *et al.* Lymphocytic leiomyositis and myenteric ganglionitis are intrinsic features of cystic fibrosis: studies in distal intestinal obstruction syndrome and meconium ileus. *J Pediatr Gastroenterol Nutr* 49, 42-51 (2009).
562. Blackman, SM, Deering-Brose, R, McWilliams, R, Naughton, K, Coleman, B, Lai, T, *et al.* Relative contribution of genetic and nongenetic modifiers to intestinal obstruction in cystic fibrosis. *Gastroenterology* 131, 1030-1039 (2006).





563. Minkes, RK, Langer, JC, Skinner, MA, Foglia, RP, O'Hagan, A, Cohen, AH, *et al.* Intestinal obstruction after lung transplantation in children with cystic fibrosis. *J Pediatr Surg* 34, 1489-1493 (1999).
564. Gilljam, M, Chaparro, C, Tullis, E, Chan, C, Keshavjee, S & Hutcheon, M. GI complications after lung transplantation in patients with cystic fibrosis. *Chest* 123, 37-41 (2003).
565. Subhi, R, Ooi, R, Finlayson, F, Kotsimbos, T, Wilson, J, Lee, WR, *et al.* Distal intestinal obstruction syndrome in cystic fibrosis: presentation, outcome and management in a tertiary hospital (2007-2012). *ANZ J Surg* 84, 740-744 (2014).
566. Morton, JR, Ansari, N, Glanville, AR, Meagher, AP & Lord, RV. Distal intestinal obstruction syndrome (DIOS) in patients with cystic fibrosis after lung transplantation. *J Gastrointest Surg* 13, 1448-1453 (2009).
567. Andersen, HO, Hjelt, K, Waever, E & Overgaard, K. The age-related incidence of meconium ileus equivalent in a cystic fibrosis population: the impact of high-energy intake. *J Pediatr Gastroenterol Nutr* 11, 356-360 (1990).
568. Dray, X, Bienvenu, T, Desmazes-Dufeu, N, Dusser, D, Marteau, P & Hubert, D. Distal intestinal obstruction syndrome in adults with cystic fibrosis. *Clin Gastroenterol Hepatol* 2, 498-503 (2004).
569. Borowitz, D & Gelfond, D. Intestinal complications of cystic fibrosis. *Curr Opin Pulm Med* 19, 676-680 (2013).
570. van der Doef, HP, Kokke, FT, van der Ent, CK & Houwen, RH. Intestinal obstruction syndromes in cystic fibrosis: meconium ileus, distal intestinal obstruction syndrome, and constipation. *Curr Gastroenterol Rep* 13, 265-270 (2011).
571. Littlewood, JM, Wolfe, SP & Conway, SP. Diagnosis and treatment of intestinal malabsorption in cystic fibrosis. *Pediatr Pulmonol* 41, 35-49 (2006).
572. Rubinstein, S, Moss, R & Lewiston, N. Constipation and meconium ileus equivalent in patients with cystic fibrosis. *Pediatrics* 78, 473-479 (1986).
573. Groves, T, K, A., Dutt, S, Gaskin, K & Fitzgerald, D. Cystic Fibrosis Frequently Asked Questions. *Paediatric Respiratory Reviews* (2016).
574. Matson, A & Bell, S. Distal Intestinal Obstruction Syndrome (DIOS) management in adult CF patients. (The Prince Charles Hospital, Chermside, Queensland, Australia, 2015).
575. Lewis, SJ & Heaton, KW. Stool form scale as a useful guide to intestinal transit time. *Scand J Gastroenterol* 32, 920-924 (1997).
576. Maisonneuve, P, Marshall, BC, Knapp, EA & Lowenfels, AB. Cancer risk in cystic fibrosis: a 20-year nationwide study from the United States. *J Natl Cancer Inst* 105, 122-129 (2013).
577. Niccum, DE, Billings, JL, Dunitz, JM & Khoruts, A. Colonoscopic screening shows increased early incidence and progression of adenomas in cystic fibrosis. *J Cyst Fibros* (2016).
578. Billings, JL, Dunitz, JM, McAllister, S, Herzog, T, Bobr, A & Khoruts, A. Early colon screening of adult patients with cystic fibrosis reveals high incidence of adenomatous colon polyps. *J Clin Gastroenterol* 48, e85-88 (2014).
579. Gory, I, Brown, G, Wilson, J, Kemp, W, Paul, E & Roberts, SK. Increased risk of colorectal neoplasia in adult patients with cystic fibrosis: a matched case-control study. *Scand J Gastroenterol* 49, 1230-1236 (2014).
580. Ledder, O, Haller, W, Couper, RT, Lewindon, P & Oliver, M. Cystic fibrosis: an update for clinicians. Part 2: hepatobiliary and pancreatic manifestations. *J Gastroenterol Hepatol* 29, 1954-1962 (2014).
581. Stonebraker, JR, Ooi, CY, Pace, RG, Corvol, H, Knowles, MR, Durie, PR, *et al.* Features of Severe Liver Disease With Portal Hypertension in Patients With Cystic Fibrosis. *Clin Gastroenterol Hepatol* (2016).
582. Bartlett, JR, Friedman, KJ, Ling, SC, Pace, RG, Bell, SC, Bourke, B, *et al.* Genetic modifiers of liver disease in cystic fibrosis. *JAMA* 302, 1076-1083 (2009).
583. Lindblad, A, Glaumann, H & Strandvik, B. Natural history of liver disease in cystic fibrosis. *Hepatology* 30, 1151-1158 (1999).
584. Nagel, RA, Westaby, D, Javaid, A, Kavani, J, Meire, HB, Lombard, MG, *et al.* Liver disease and bile duct abnormalities in adults with cystic fibrosis. *Lancet* 2, 1422-1425 (1989).
585. Corbett, K, Kelleher, S, Rowland, M, Daly, L, Drumm, B, Canny, G, *et al.* Cystic fibrosis-associated liver disease: a population-based study. *J Pediatr* 145, 327-332 (2004).
586. Brigman, C & Feranchak, A. Liver involvement in cystic fibrosis. *Curr Treat Options Gastroenterol* 9, 484-496 (2006).
587. Vawter, GF & Shwachman, H. Cystic fibrosis in adults: an autopsy study. *Pathol Annu* 14 Pt 2, 357-382 (1979).
588. Kobelska-Dubiel, N, Klincewicz, B & Cichy, W. Liver disease in cystic fibrosis. *Przegląd Gastroenterologiczny* 9, 136-141 (2014).
589. Patton, H. Nutritional assessment of patients with chronic liver disease. *Gastroenterology and Hepatology* 8, 687-690 (2012).
590. Flass, T, Tong, S, Frank, DN, Wagner, BD, Robertson, CE, Vogel Kotter, C, *et al.* Intestinal lesions are associated with altered intestinal microbiome and are more frequent in children and young adults with cystic fibrosis and cirrhosis. *PLoS ONE* 10(2015).
591. Rowland, M, Gallagher, CG, O'Laoide, R, Canny, G, Broderick, A, Hayes, R, *et al.* Outcome in cystic fibrosis liver disease. *Am J Gastroenterol* 106, 104-109 (2011).
592. Sabharwal, S. Gastrointestinal Manifestations of Cystic Fibrosis. *Gastroenterol Hepatol (N Y)* 12, 43-47 (2016).
593. Lewindon, PJ, Shepherd, RW, Walsh, MJ, Greer, RM, Williamson, R, Pereira, TN, *et al.* Importance of hepatic fibrosis in cystic fibrosis and the predictive value of liver biopsy. *Hepatology* 53, 193-201 (2011).

594. Minicucci, L, Lorini, R, Giannattasio, A, Colombo, C, Iapichino, L, Reali, MF, *et al.* Liver disease as risk factor for cystic fibrosis-related diabetes development. *Acta Paediatr* 96, 736-739 (2007).
595. Cheng, K, Ashby, D & Smyth, RL. Ursodeoxycholic acid for cystic fibrosis-related liver disease. *Cochrane Database Syst Rev*, Cd000222 (2014).
596. Ooi, CY, Nightingale, S, Durie, PR & Freedman, SD. Ursodeoxycholic acid in cystic fibrosis-associated liver disease. in *J Cyst Fibros*, Vol. 11 72-73; author reply 74-75 (Netherlands, 2012).
597. Camilleri, M, Parkman, HP, Shafi, MA, Abell, TL & Gerson, L. Clinical guideline: management of gastroparesis. *Am J Gastroenterol* 108, 18-37; quiz 38 (2013).
598. Bodet-Milin, C, Querellou, S, Oudoux, A, Haloun, A, Horeau-Langlard, D, Carlier, T, *et al.* Delayed gastric emptying scintigraphy in cystic fibrosis patients before and after lung transplantation. *The Journal of Heart and Lung Transplantation* 25, 1077-1083 (2006).
599. Malik, BA, Xie, YY, Wine, E & Huynh, HQ. Diagnosis and pharmacological management of small intestinal bacterial overgrowth in children with intestinal failure. *Can J Gastroenterol* 25, 41-45 (2011).
600. Wilschanski, M & Durie, PR. Patterns of GI disease in adulthood associated with mutations in the CFTR gene. *Gut* 56, 1153-1163 (2007).
601. Fluge, G, Olesen, HV, Gilljam, M, Meyer, P, Pressler, T, Storrosten, OT, *et al.* Co-morbidity of cystic fibrosis and celiac disease in Scandinavian cystic fibrosis patients. *J Cyst Fibros* 8, 198-202 (2009).
602. Lloyd-Still, JD. Crohn's disease and cystic fibrosis. *Dig Dis Sci* 39, 880-885 (1994).
603. Bresso, F, Askling, J, Astegiano, M, Demarchi, B, Sapone, N, Rizzetto, M, *et al.* Potential role for the common cystic fibrosis DeltaF508 mutation in Crohn's disease. *Inflamm Bowel Dis* 13, 531-536 (2007).
604. Kelly, A & Moran, A. Update on cystic fibrosis-related diabetes. *J Cyst Fibros* 12, 318-331 (2013).
605. Moran, A, Becker, D, Casella, SJ, Gottlieb, PA, Kirkman, MS, Marshall, BC, *et al.* Epidemiology, pathophysiology, and prognostic implications of cystic fibrosis-related diabetes: a technical review. *Diabetes Care* 33, 2677-2683 (2010).
606. Dunning, T. *Diabetes Education, in Care of People with Diabetes: A Manual of Nursing Practice*, (Wiley-Blackwell, Oxford, UK, 2009).
607. Moran, A, Doherty, L, Wang, X & Thomas, W. Abnormal glucose metabolism in cystic fibrosis. *J Pediatr* 133, 10-17 (1998).
608. Moran, A, Milla, C, Ducret, R & Nair, KS. Protein metabolism in clinically stable adult cystic fibrosis patients with abnormal glucose tolerance. *Diabetes* 50, 1336-1343 (2001).
609. American Diabetes Association. Standards of Medical Care in Diabetes 2014. *Diabetes Care* 37 Suppl 1, S14-80 (2014).
610. Lannig, S, Thorsteinsson, B, Nerup, J & Koch, C. Diabetes mellitus in cystic fibrosis: effect of insulin therapy on lung function and infections. *Acta Paediatr* 83, 849-853 (1994).
611. Moran, A, Pekow, P, Grover, P, Zom, M, Slovis, B, Pilewski, J, *et al.* Insulin Therapy to Improve BMI in Cystic Fibrosis-Related Diabetes Without Fasting Hyperglycaemia. *Diabetes Care* 32, 1783-1788 (2009).
612. Graham, C, Ushagowitchal, J & Crowder, T. Review of current practice in nutrition management in Australia and New Zealand. (Cystic Fibrosis Australia, 2011).
613. Guo, JH, Chen, H, Ruan, YC, Zhang, XL, Zhang, XH, Fok, KL, *et al.* Glucose-induced electrical activities and insulin secretion in pancreatic islet beta-cells are modulated by CFTR. *Nat Commun* 5, 4420 (2014).
614. Tsabari, R, Elyashar, HI, Cymberknowh, MC, Breuer, O, Armoni, S, Livnat, G, *et al.* CFTR potentiator therapy ameliorates impaired insulin secretion in CF patients with a gating mutation. *J Cyst Fibros* 15, e25-27 (2016).
615. Moran, A, Brunzell, C, Cohen, RC, Katz, M, Marshall, BC, Onady, G, *et al.* Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. *Diabetes Care* 33, 2697-2708 (2010).
616. Rana, M, Munns, CF, Selvadurai, HC, Simonds, S, Cooper, PJ, Woodhead, HJ, *et al.* Increased detection of cystic-fibrosis-related diabetes in Australia. *Arch Dis Child* 96, 823-826 (2011).
617. Sheikh, S & Kelly, A. Cystic fibrosis-related diabetes: links, challenges and future directions. *Dovepress* 5, 157-167 (2015).
618. Kuo, P, Stevens, JE, Russo, A, Maddox, A, Wishart, JM, Jones, KL, *et al.* Gastric emptying, incretin hormone secretion, and postprandial glycemia in cystic fibrosis - Effects of pancreatic enzyme supplementation. *Journal of Clinical Endocrinology and Metabolism* 96, E851-E855 (2011).
619. Middleton, PG, Wagenaar, M, Matson, AG, Craig, ME, Holmes-Walker, DJ, Katz, T, *et al.* Australian standards of care for cystic fibrosis-related diabetes. *Respirology* 19, 185-192 (2014).
620. Burgess, JC, Bridges, N, Banya, W, Gyi, KM, Hodson, ME, Bilton, D, *et al.* HbA1c as a screening tool for cystic fibrosis related diabetes. *J Cyst Fibros* 15, 251-257 (2016).
621. Schnyder, MA, Benden, C & Schmid, C. HbA1c: An effective screening tool for cystic fibrosis related diabetes? *J Cyst Fibros* 15, 261-262 (2016).
622. Widger, J, Hameed, S, Ooi, CY & Verge, C. Using HbA1c as a screening tool for Cystic Fibrosis Related Diabetes. *J Cyst Fibros* 15, 263-264 (2016).



623. Australian Diabetes Educators Association. Use of blood glucose meters. (Australian Diabetes Educators Association, Sydney, Australia, 2015). <https://www.adea.com.au>
624. Metzger, BE, Lowe, LP, Dyer, AR, Trimble, ER, Chaovarindr, U, Coustan, DR, *et al.* Hyperglycemia and adverse pregnancy outcomes. *N Engl J Med* 358, 1991-2002 (2008).
625. Nankervis, A, McIntyre, HD, Moses, R, Ross, GP, Callaway, L, Porter, C, *et al.* ADIPS Consensus Guidelines for the Testing and Diagnosis for Gestational Diabetes Mellitus in Australia. (2013). <http://adips.org/downloads/ADIPSConsensusGuidelinesGDM-03.05.13VersionACCEPTEDFINAL.pdf>
626. Armaghanian, N, Brand-Miller, JC, Markovic, TP & Steinbeck, KS. Hypoglycaemia in cystic fibrosis in the absence of diabetes: A systematic review. *J Cyst Fibros* (2016).
627. Battezzati, A, Battezzati, PM, Costantini, D, Seia, M, Zazzeron, L, Russo, MC, *et al.* Spontaneous hypoglycemia in patients with cystic fibrosis. *Eur J Endocrinol* 156, 369-376 (2007).
628. Moran, A, Diem, P, Klein, DJ, Levitt, MD & Robertson, RP. Pancreatic endocrine function in cystic fibrosis. *J Pediatr* 118, 715-723 (1991).
629. Hardin, DS, Rice, J, Rice, M & Rosenblatt, R. Use of the insulin pump in treat cystic fibrosis related diabetes. *J Cyst Fibros* 8, 174-178 (2009).
630. Scheuing, N, Badenhoop, K, Borkenstein, M, Konrad, K, Lilienthal, E, Laubner, K, *et al.* Why is insulin pump treatment rarely used in adolescents and young adults with cystic fibrosis-related diabetes? *Pediatr Diabetes* 16, 10-15 (2015).
631. UK Cystic Fibrosis Trust Diabetes Working Group. Management of cystic fibrosis related diabetes mellitus. (Cystic Fibrosis Trust, United Kingdom, 2004). <https://www.cysticfibrosis.org.uk/the-work-we-do/clinical-care/consensus-documents>
632. Mackie, AD, Thornton, SJ & Edenborough, FP. Cystic fibrosis-related diabetes. *Diabet Med* 20, 425-436 (2003).
633. Edenborough, FP, Borgo, G, Knoop, C, Lanefors, L, Mackenzie, WE, Madge, S, *et al.* Guidelines for the management of pregnancy in women with cystic fibrosis. *J Cyst Fibros* 7 Suppl 1, S2-32 (2008).
634. Moran, A, Hardin, D, Rodman, D, Allen, HF, Beall, RJ, Borowitz, D, *et al.* Diagnosis, screening and management of cystic fibrosis related diabetes mellitus: a consensus conference report. *Diabetes Res Clin Pract* 45, 61-73 (1999).
635. Matson, AG, Walker, F, Matson, KM & Bell, S. Prevalance of cystic fibrosis related diabetes (CFRD), in an Australian adult cystic fibrosis (CF) unit. *Journal of Cystic Fibrosis* (2010).
636. Rosenecker, J, Eichler, I, Barmeier, H & von der Hardt, H. Diabetes mellitus and cystic fibrosis: comparison of clinical parameters in patients treated with insulin versus oral glucose-lowering agents. *Pediatr Pulmonol* 32, 351-355 (2001).
637. Zipf, W. Therapeutic options for treatment of diabetes mellitus in cystic fibrosis. . *Pediatric Pulmonology. Supplement*, 5, . 111-114 (1995).
638. Australian Diabetes Educators Association. Guidelines and standards. (Australian Diabetes Educators Association, Sydney, Australia, 2016). <https://www.adea.com.au/resources/for-health-professionals/guidelines-and-standards/>
639. Dietitians Association of Australia and Australian Diabetes Educators Association. The role of credentialled diabetes educators and accredited practising dietitians in the delivery of diabetes self management and nutrition services for people with diabetes. (Dietitian's Association of Australia and Australian Diabetes Educators Association, Australia, 2015). <http://daa.asn.au/wp-content/uploads/2013/09/ADEA-and-DAA-Joint-Statement-FINAL.pdf>
640. Hameed, S, Morton, JR, Field, PI, Belessis, Y, Yoong, T, Katz, T, *et al.* Once daily insulin detemir in cystic fibrosis with insulin deficiency. *Arch Dis Child* 97, 464-467 (2012).
641. Amiel, SA, Pursey, N, Higgins, B, Dawoud, D & Guideline Development, G. Diagnosis and management of type 1 diabetes in adults: summary of updated NICE guidance. *BMJ* 351, h4188 (2015).
642. National Institute for Health and Care Excellence. Type 1 Diabetes in Adults: Diagnosis and Management. NICE Guideline. (National Institute for Health and Care Excellence, 2015). <https://www.nice.org.uk/guidance/ng17>
643. Lanng, S, Thorsteinsson, B, Lund-Andersen, C, Nerup, J, Schiøtz, PO & Koch, C. Diabetes mellitus in Danish cystic fibrosis patients: prevalence and late diabetic complications. *Acta Paediatr* 83, 72-77 (1994).
644. Jacquot, J, Delion, M, Gangloff, S, Braux, J & Velard, F. Bone disease in cystic fibrosis: new pathogenic insights opening novel therapies. *Osteoporos Int* 27, 1401-1412 (2016).
645. Paccou, J, Zeboulon, N, Combescure, C, Gossec, L & Cortet, B. The prevalence of osteoporosis, osteopenia, and fractures among adults with cystic fibrosis: a systematic literature review with meta-analysis. *Calcif Tissue Int* 86, 1-7 (2010).
646. Aris, RM, Renner, JB, Winders, AD, Buell, HE, Riggs, DB, Lester, GE, *et al.* Increased rate of fractures and severe kyphosis: sequelae of living into adulthood with cystic fibrosis. *Ann Intern Med* 128, 186-193 (1998).
647. Henderson, RC & Madsen, CD. Bone mineral content and body composition in children and young adults with cystic fibrosis. *Pediatr Pulmonol* 27, 80-84 (1999).
648. Frangolias, DD, Pare, PD, Kendler, DL, Davidson, AG, Wong, L, Raboud, J, *et al.* Role of exercise and nutrition status on bone mineral density in cystic fibrosis. *J Cyst Fibros* 2, 163-170 (2003).
649. Buntain, HM, Greer, RM, Schluter, PJ, Wong, JC, Batch, JA, Potter, JM, *et al.* Bone mineral density in Australian children, adolescents and adults with cystic fibrosis: a controlled cross sectional study. *Thorax* 59, 149-155 (2004).
650. Gore, AP, Kwon, SH & Stenbit, AE. A roadmap to the brittle bones of cystic fibrosis. *J Osteoporos* 2011, 926045 (2010).

651. Gronowitz, E, Lorentzon, M, Ohlsson, C, Mellstrom, D & Strandvik, B. Docosahexaenoic acid is associated with endosteal circumference in long bones in young males with cystic fibrosis. *Br J Nutr* 99, 160-167 (2008).
652. Gronowitz, E, Mellstrom, D & Strandvik, B. Serum phospholipid fatty acid pattern is associated with bone mineral density in children, but not adults, with cystic fibrosis. *Br J Nutr* 95, 1159-1165 (2006).
653. Gronowitz, E, Garemo, M, Lindblad, A, Mellstrom, D & Strandvik, B. Decreased bone mineral density in normal-growing patients with cystic fibrosis. *Acta Paediatr* 92, 688-693 (2003).
654. Hofbauer, LC, Gori, F, Riggs, BL, Lacey, DL, Dunstan, CR, Spelsberg, TC, *et al.* Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. *Endocrinology* 140, 4382-4389 (1999).
655. National Institute for Health and Clinical Excellence. Osteoporosis: assessing the risk of fragility fracture. (National Institute for Health and Clinical Excellence, Manchester, United Kingdom, 2012). <https://www.nice.org.uk/guidance/cg146/resources/osteoporosis-assessing-the-risk-of-fragility-fracture-35109574194373>
656. Elkin, SL, Fairney, A, Burnett, S, Kemp, M, Kyd, P, Burgess, J, *et al.* Vertebral deformities and low bone mineral density in adults with cystic fibrosis: a cross-sectional study. *Osteoporos Int* 12, 366-372 (2001).
657. Shead, EF, Haworth, CS, Condliffe, AM, McKeon, DJ, Scott, MA & Compston, JE. Cystic fibrosis transmembrane conductance regulator (CFTR) is expressed in human bone. in *Thorax*, Vol. 62 650-651 (England, 2007).
658. Stalvey, MS, Clines, KL, Havasi, V, McKibbin, CR, Dunn, LK, Chung, WJ, *et al.* Osteoblast CFTR inactivation reduces differentiation and osteoprotegerin expression in a mouse model of cystic fibrosis-related bone disease. *PLoS One* 8, e80098 (2013).
659. Bhudhikanok, GS, Wang, MC, Marcus, R, Harkins, A, Moss, RB & Bachrach, LK. Bone acquisition and loss in children and adults with cystic fibrosis: a longitudinal study. *J Pediatr* 133, 18-27 (1998).
660. Haworth, CS, Selby, PL, Webb, AK, Dodd, ME, Musson, H, Mc, LNR, *et al.* Low bone mineral density in adults with cystic fibrosis. *Thorax* 54, 961-967 (1999).
661. Hwang, IR, Choi, YK, Lee, WK, Kim, JG, Lee, IK, Kim, SW, *et al.* Association between prolonged breastfeeding and bone mineral density and osteoporosis in postmenopausal women: KNHANES 2010-2011. *Osteoporos Int* 27, 257-265 (2016).
662. World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. *World Health Organ Tech Rep Ser* 843, 1-129 (1994).
663. Kanis, JA, Melton, LJ, 3rd, Christiansen, C, Johnston, CC & Khaltaev, N. The diagnosis of osteoporosis. *J Bone Miner Res* 9, 1137-1141 (1994).
664. Fairweather-Tait, SJ, Skinner, J, Guile, GR, Cassidy, A, Spector, TD & MacGregor, AJ. Diet and bone mineral density study in postmenopausal women from the TwinsUK registry shows a negative association with a traditional English dietary pattern and a positive association with wine. *Am J Clin Nutr* 94, 1371-1375 (2011).
665. McNaughton, SA, Wattanapenpaiboon, N, Wark, JD & Nowson, CA. An energy-dense, nutrient-poor dietary pattern is inversely associated with bone health in women. *J Nutr* 141, 1516-1523 (2011).
666. Legroux-Gerot, I, Leroy, S, Prudhomme, C, Perez, T, Flipo, RM, Wallaert, B, *et al.* Bone loss in adults with cystic fibrosis: prevalence, associated factors, and usefulness of biological markers. *Joint Bone Spine* 79, 73-77 (2012).
667. Kanayama, G, Hudson, JI & Pope, HG, Jr. Illicit anabolic-androgenic steroid use. *Horm Behav* 58, 111-121 (2010).
668. Paxton, GA, Teale, GR, Nowson, CA, Mason, RS, McGrath, JJ, Thompson, MJ, *et al.* Vitamin D and health in pregnancy, infants, children and adolescents in Australia and New Zealand: a position statement. *Med J Aust* 198, 142-143 (2013).
669. Hind, K, Truscott, JG & Conway, SP. Exercise during childhood and adolescence: a prophylaxis against cystic fibrosis-related low bone mineral density? Exercise for bone health in children with cystic fibrosis. *J Cyst Fibros* 7, 270-276 (2008).
670. Tejero Garcia, S, Giraldez Sanchez, MA, Cejudo, P, Quintana Gallego, E, Dapena, J, Garcia Jimenez, R, *et al.* Bone health, daily physical activity, and exercise tolerance in patients with cystic fibrosis. *Chest* 140, 475-481 (2011).
671. Sanders, KM, Nowson, CA, Kotowicz, MA, Briffa, K, Devine, A & Reid, IR. Calcium and bone health: position statement for the Australian and New Zealand Bone and Mineral Society, Osteoporosis Australia and the Endocrine Society of Australia. *Med J Aust* 190, 316-320 (2009).
672. Chapman, I, Greville, H, Ebeling, PR, King, SJ, Kotsimbos, T, Nugent, P, *et al.* Intravenous zoledronate improves bone density in adults with cystic fibrosis (CF). *Clin Endocrinol (Oxf)* 70, 838-846 (2009).
673. Cystic Fibrosis Australia. Cystic Fibrosis in Australia 2012 - 15th Annual Report from the Australian Cystic Fibrosis Data Registry. (North Ryde, Australia, 2012). [http://www.cysticfibrosis.org.au/media/wysiwyg/CF-Australia/medical-documents/ACFDR\\_2012/ACFDR\\_Annual\\_Report\\_2012r.pdf](http://www.cysticfibrosis.org.au/media/wysiwyg/CF-Australia/medical-documents/ACFDR_2012/ACFDR_Annual_Report_2012r.pdf)
674. Goss, CH, Rubenfeld, GD, Otto, K & Aitken, ML. The effect of pregnancy on survival in women with cystic fibrosis. *Chest* 124, 1460-1468 (2003).
675. Geake, j, Tay, G, Callaway, L & Bell, SC. Pregnancy and Cystic Fibrosis: Approach to contemporary management. *Obstetric Medicine* 7, 147 - 155 (2014).
676. Ahluwalia, M, Hoag, JB, Hadeh, A, Ferrin, M & Hadjiliadis, D. Cystic fibrosis and pregnancy in the modern era: a case control study. *J Cyst Fibros* 13, 69-73 (2014).





677. Michel, SH & Mueller, DH. Nutrition for pregnant women who have cystic fibrosis. *J Acad Nutr Diet* 112, 1943-1948 (2012).
678. Food Standards Australia and New Zealand. Folic acid/folate and pregnancy. (Food Standards Australia and New Zealand, 2016). <http://www.foodstandards.gov.au/consumer/generalissues/pregnancy/folic/Pages/default.aspx>
679. Whitty, JE. Cystic fibrosis in pregnancy. *Clin Obstet Gynecol* 53, 369-376 (2010).
680. New Zealand Ministry of Health. Healthy weight gain during pregnancy. (New Zealand Government Ministry of Health, Wellington New Zealand, 2014). <http://www.health.govt.nz/your-health/healthy-living/food-and-physical-activity/healthy-eating/healthy-weight-gain-during-pregnancy>
681. Hilman, BC, Aitken, ML & Constantinescu, M. Pregnancy in patients with cystic fibrosis. *Clin Obstet Gynecol* 39, 70-86 (1996).
682. U.S. CF Foundation, Johns Hopkins University & The Hospital for Sick Children. The Clinical and Functional TRanslation of CFTR (CFTR2). Vol. 2016 (2011). <http://cftr2.org/>
683. Bell, SC, De Boeck, K & Amaral, MD. New pharmacological approaches for cystic fibrosis: promises, progress, pitfalls. *Pharmacol Ther* 145, 19-34 (2015).
684. Brodli, M, Haq, IJ, Roberts, K & Elborn, JS. Targeted therapies to improve CFTR function in cystic fibrosis. *Genome Med* 7, 101 (2015).
685. The Pharmaceutical Benefits Scheme. Ivacaftor tablet. (Australian Government, Department of Health, Australia, 2013). <http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2013-07/ivacaftor>
686. The Pharmaceutical Benefits Scheme. Ivacaftor. Vol. 2016 (Australian Government Department of Health, 2016). <http://www.pbs.gov.au/medicine/item/10170G-10175M>
687. Wainwright, CE, Elborn, JS & Ramsey, BW. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. *N Engl J Med* 373, 1783-1784 (2015).
688. Tierney, AC, Edgeworth, D, Williams, E, Finlayson, F, Keating, D, Clark, D, *et al.* ePS05.3 Ivacaftor and its effects on body composition in adults with G551D related cystic fibrosis. *Journal of Cystic Fibrosis* 14, S50 (2016).
689. McKay, K, Cheah, E, Venuti, E & Gaskin, K. The effect of ivacaftor on exocrine pancreatic function in patients with cystic fibrosis and the G551D CFTR mutation who are naïve for ivacaftor. *J Cyst Fibros* 14, S117 (2015).
690. Bodewes, FA, Verkade, HJ, Taminiau, JA, Borowitz, D & Wilschanski, M. Cystic fibrosis and the role of gastrointestinal outcome measures in the new era of therapeutic CFTR modulation. *J Cyst Fibros* 14, 169-177 (2015).
691. Safe, M, Gifford, AJ, Jaffe, A & Ooi, CY. Resolution of Intestinal Histopathology Changes in Cystic Fibrosis after Treatment with Ivacaftor. *Ann Am Thorac Soc* 13, 297-298 (2016).
692. Borowitz, D, Lubarsky, B, Wilschanski, M, Munck, A, Gelfond, D, Bodewes, F, *et al.* Nutritional Status Improved in Cystic Fibrosis Patients with the G551D Mutation After Treatment with Ivacaftor. *Dig Dis Sci* 61, 198-207 (2016).
693. Vertex Pharmaceuticals Incorporated. Investigator's Brochure Ivacaftor (VX-770). (Vertex Pharmaceuticals Incorporated, Boston, USA., 2015). <http://www.vrtx.com/>
694. Therapeutic Goods Administration. Australian regulatory guidelines for complementary medicines. Vol. 6 1-163 (Australian Government Department of Health, Australia, 2016).
695. Molassiotis, A, Fernadez-Ortega, P, Pud, D, Ozden, G, Scott, JA, Panteli, V, *et al.* Use of complementary and alternative medicine in cancer patients: a European survey. *Ann Oncol* 16, 655-663 (2005).
696. Giangioppo, S, Fleischer, E, Ittermann, J, Price, A, Lyttle, B & Radhakrishnan, D. Complementary and alternative medicine use in children with Cystic Fibrosis *Pediatric Pulmonology* 48, 443 - 443 (2013).
697. Tanase, A & Zanni, R. The use of complementary and alternative medicine among pediatric cystic fibrosis patients. *J Altern Complement Med* 14, 1271-1273 (2008).
698. Burrows, JA, Bajramovic, J & Bell, SC. Prevalence of Complementary and Alternative Medicine Use by Adults with Cystic Fibrosis. *Journal of Pharmacy Practice and Research* 32, 320-323 (2002).
699. New Zealand Ministry of Health. Natural Health and Supplementary Products Bill. (New Zealand Government, Ministry of Health, Health Committee, 2012). <http://www.legislation.govt.nz/bill/government/2011/0324/latest/versions.aspx>
700. Whelan, K & Quigley, EM. Probiotics in the management of irritable bowel syndrome and inflammatory bowel disease. *Curr Opin Gastroenterol* 29, 184-189 (2013).
701. Palmer, C, Bik, EM, DiGiulio, DB, Relman, DA & Brown, PO. Development of the human infant intestinal microbiota. *PLoS Biol* 5, e177 (2007).
702. Yatsunenkov, T, Rey, FE, Manary, MJ, Trehan, I, Dominguez-Bello, MG, Contreras, M, *et al.* Human gut microbiome viewed across age and geography. *Nature* 486, 222-227 (2012).
703. World Gastroenterology Organisation. World Gastroenterology Organisation global guidelines probiotics and prebiotics. (Milwaukee, USA, 2011). <http://www.worldgastroenterology.org/guidelines/global-guidelines/probiotics-and-prebiotics/probiotics-and-prebiotics-english>
704. Faith, JJ, Guruge, JL, Charbonneau, M, Subramanian, S, Seedorf, H, Goodman, AL, *et al.* The long-term stability of the human gut microbiota. *Science* 341, 1237439 (2013).

705. Collado, MC, Cernada, M, Bauerl, C, Vento, M & Perez-Martinez, G. Microbial ecology and host-microbiota interactions during early life stages. *Gut Microbes* 3, 352-365 (2012).
706. Sartor, RB. Probiotic therapy of intestinal inflammation and infections. *Curr Opin Gastroenterol* 21, 44-50 (2005).
707. Anderson, JL, Miles, C & Tierney, AC. Effect of probiotics on respiratory, gastrointestinal and nutritional outcomes in patients with cystic fibrosis: A systematic review. *J Cyst Fibros* (2016).
708. Ciorba, MA. A gastroenterologist's guide to probiotics. *Clin Gastroenterol Hepatol* 10, 960-968 (2012).
709. Food and Agriculture Organization of the United Nations and World Health Organization. Report of a Joint FAO/WHO Expert Consultation on Evaluation of Health and Nutritional Properties of Probiotics in Food Including Powder Milk with Live Lactic Acid Bacteria. (Córdoba, Argentina, 2001). <http://www.fao.org/3/a-a0512e.pdf>
710. Madsen, K. Probiotics and the immune response. *J Clin Gastroenterol* 40, 232-234 (2006).
711. Petrof, E, O. Probiotics and Gastrointestinal Disease: Clinical Evidence and Basic Science. *Antiinflamm Antiallergy Agents Med Chem* 8, 260 - 269 (2009).
712. Li, L & Somers, S. The clinical significance of the gut microbiota in cystic fibrosis and the potential for dietary therapies. *Clin Nutr* 33, 571-580 (2014).
713. Duytschaever, G, Huys, G, Bekaert, M, Boulanger, L, De Boeck, K & Vandamme, P. Cross-sectional and longitudinal comparisons of the predominant fecal microbiota compositions of a group of pediatric patients with cystic fibrosis and their healthy siblings. *Appl Environ Microbiol* 77, 8015-8024 (2011).
714. Duytschaever, G, Huys, G, Bekaert, M, Boulanger, L, De Boeck, K & Vandamme, P. Dysbiosis of bifidobacteria and Clostridium cluster XIVa in the cystic fibrosis fecal microbiota. *J Cyst Fibros* 12, 206-215 (2013).
715. Madan, JC, Koestler, DC, Stanton, BA, Davidson, L, Moulton, LA, Housman, ML, *et al.* Serial analysis of the gut and respiratory microbiome in cystic fibrosis in infancy: interaction between intestinal and respiratory tracts and impact of nutritional exposures. *MBio* 3(2012).
716. Nagalingam, NA, Cope, EK & Lynch, SV. Probiotic strategies for treatment of respiratory diseases. *Trends Microbiol* 21, 485-492 (2013).
717. Quigley, EMM. Gut Bacteria in Health and Disease. *Gastroenterology and Hepatology* 9, 560-569 (2013).
718. Hempel, S, Newberry, S, Ruelaz, A, Wang, Z, Miles, JN, Suttrop, MJ, *et al.* Safety of probiotics used to reduce risk and prevent or treat disease. *Evid Rep Technol Assess (Full Rep)*, 1-645 (2011).
719. Van den Nieuwboer, M, Brummer, RJ, Guarner, F, Morelli, L, Cabana, M & Claasen, E. The administration of probiotics and synbiotics in immune compromised adults: is it safe? *Benef Microbes* 6, 3-17 (2015).
720. Sanders, ME. Impact of probiotics on colonizing microbiota of the gut. *J Clin Gastroenterol* 45 Suppl, S115-119 (2011).
721. Australian Medical Association. AMA Position Statement: Complementary Medicine. (Australian Medical Association, Australia, 2012). [https://ama.com.au/system/tdf/documents/AMA\\_Position\\_Statement\\_Complementary\\_Medicine.pdf?file=1&type=node&id=40659](https://ama.com.au/system/tdf/documents/AMA_Position_Statement_Complementary_Medicine.pdf?file=1&type=node&id=40659).
722. Whelan, K & Dimidi, E. Probiotics. (ed. Association, T.B.D.) (The British Dietetic Association, 2015). <https://www.bda.uk.com/foodfacts/probiotics.pdf>
723. Bishop, C, Hudson, VM, Hilton, SC & Wilde, C. A pilot study of the effect of inhaled buffered reduced glutathione on the clinical status of patients with cystic fibrosis. *Chest* 127, 308-317 (2005).
724. Eyres, L, Eyres, MF, Chisholm, A & Brown, RC. Coconut oil consumption and cardiovascular risk factors in humans. *Nutr Rev* 74, 267-280 (2016).
725. Braga, SF & Almgren, MM. Complementary therapies in cystic fibrosis: nutritional supplements and herbal products. *J Pharm Pract* 26, 14-17 (2013).
726. Bjarnsholt, T, Jensen, PO, Burmolle, M, Hentzer, M, Haagensen, JA, Hougen, HP, *et al.* Pseudomonas aeruginosa tolerance to tobramycin, hydrogen peroxide and polymorphonuclear leukocytes is quorum-sensing dependent. *Microbiology* 151, 373-383 (2005).
727. Strimpakos, AS & Sharma, RA. Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials. *Antioxid Redox Signal* 10, 511-545 (2008).
728. Egan, ME, Pearson, M, Weiner, SA, Rajendran, V, Rubin, D, Glockner-Pagel, J, *et al.* Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects. *Science* 304, 600-602 (2004).
729. Berger, AL, Randak, CO, Ostedgaard, LS, Karp, PH, Vermeer, DW & Welsh, MJ. Curcumin stimulates cystic fibrosis transmembrane conductance regulator Cl<sup>-</sup> channel activity. *J Biol Chem* 280, 5221-5226 (2005).
730. Dragomir, A, Bjorstad, J, Hjelte, L & Roomans, GM. Curcumin does not stimulate cAMP-mediated chloride transport in cystic fibrosis airway epithelial cells. *Biochem Biophys Res Commun* 322, 447-451 (2004).
731. Wang, W, Bernard, K, Li, G & Kirk, KL. Curcumin opens cystic fibrosis transmembrane conductance regulator channels by a novel mechanism that requires neither ATP binding nor dimerization of the nucleotide-binding domains. *J Biol Chem* 282, 4533-4544 (2007).
732. Lipecka, J, Norez, C, Bensalem, N, Baudouin-Legros, M, Planelles, G, Becq, F, *et al.* Rescue of DeltaF508-CFTR (cystic fibrosis transmembrane conductance regulator) by curcumin: involvement of the keratin 18 network. *J Pharmacol Exp Ther* 317, 500-505 (2006).



733. Bernard, K, Wang, W, Narlawar, R, Schmidt, B & Kirk, KL. Curcumin cross-links cystic fibrosis transmembrane conductance regulator (CFTR) polypeptides and potentiates CFTR channel activity by distinct mechanisms. *J Biol Chem* 284, 30754-30765 (2009).
734. Hao, LM, Xin, LIU, Xu, LN, Na, ZHU, Sen, LIN, Hou, SG, *et al.* Natural compound curcumin corrects the gating defect of G551Dmutant cystic fibrosis transmembrane conductance regulator. *Chemical Research in Chinese Universities* 24, 92 - 95 (2008).
735. Xin, LIU, Li, GUAN, He, CY, Zhang, XJ, Xu, LN, Shang, DJ, *et al.* Natural Compound Curcumin—a Channel Potentiator Rather Than a Corrector of the Defective Intracellular Processing of  $\Delta F508$  Mutant Cystic Fibrosis Transmembrane Conductance Regulator. *Chemical Research in Chinese Universities* 24, 200 - 203 (2008).
736. Alipour, M, Omri, A & Suntres, ZE. Ginseng aqueous extract attenuates the production of virulence factors, stimulates twitching and adhesion, and eradicates biofilms of *Pseudomonas aeruginosa*. *Can J Physiol Pharmacol* 89, 419-427 (2011).
737. Song, Z, Wu, H, Mathee, K, Hoiby, N & Kharazmi, A. Gerimax ginseng regulates both humoral and cellular immunity during chronic *Pseudomonas aeruginosa* lung infection. *J Altern Complement Med* 8, 459-466 (2002).
738. Hofer, M, Benden, C, Inci, I, Schmid, C, Irani, S, Speich, R, *et al.* True survival benefit of lung transplantation for cystic fibrosis patients: the Zurich experience. *J Heart Lung Transplant* 28, 334-339 (2009).
739. Lederer, DJ, Wilt, JS, D'Ovidio, F, Bacchetta, MD, Shah, L, Ravichandran, S, *et al.* Obesity and underweight are associated with an increased risk of death after lung transplantation. *Am J Respir Crit Care Med* 180, 887-895 (2009).
740. Allen, JG, Arnaoutakis, GJ, Weiss, ES, Merlo, CA, Conte, JV & Shah, AS. The impact of recipient body mass index on survival after lung transplantation. *J Heart Lung Transplant* 29, 1026-1033 (2010).
741. Singer, JP, Peterson, ER, Snyder, ME, Katz, PP, Golden, JA, D'Ovidio, F, *et al.* Body composition and mortality after adult lung transplantation in the United States. *Am J Respir Crit Care Med* 190, 1012-1021 (2014).
742. Keogh, A, Williams, T & Pettersson, R. Australia and New Zealand Cardiothoracic Organ Transplant Registry, Annual Report, 1984-2015. (2015).
743. Benden, C. Specific aspects of children and adolescents undergoing lung transplantation. *Curr Opin Organ Transplant* 17, 509-514 (2012).
744. Rama, JA, Fan, LL, Faro, A, Elidemir, O, Morales, DL, Heinle, JS, *et al.* Lung transplantation for childhood diffuse lung disease. *Pediatr Pulmonol* 48, 490-496 (2013).
745. Huddleston, CB. Pediatric lung transplantation. *Curr Treat Options Cardiovasc Med* 13, 68-78 (2011).
746. Goldfarb, SB, Benden, C, Edwards, LB, Kucheryavaya, AY, Dipchand, AI, Levvey, BJ, *et al.* The Registry of the International Society for Heart and Lung Transplantation: Eighteenth Official Pediatric Lung and Heart-Lung Transplantation Report--2015; Focus Theme: Early Graft Failure. *J Heart Lung Transplant* 34, 1255-1263 (2015).
747. Weill, D, Benden, C, Corris, PA, Dark, JH, Davis, RD, Keshavjee, S, *et al.* A consensus document for the selection of lung transplant candidates: 2014--an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. *J Heart Lung Transplant* 34, 1-15 (2015).
748. Morrell, MR & Pilewski, JM. Lung Transplantation for Cystic Fibrosis. *Clin Chest Med* 37, 127-138 (2016).
749. Yusen, RD, Edwards, LB, Kucheryavaya, AY, Benden, C, Dipchand, AI, Goldfarb, SB, *et al.* The Registry of the International Society for Heart and Lung Transplantation: Thirty-second Official Adult Lung and Heart-Lung Transplantation Report--2015; Focus Theme: Early Graft Failure. *J Heart Lung Transplant* 34, 1264-1277 (2015).
750. Egan, JJ, Woodcock, AA & Webb, AK. Management of cystic fibrosis before and after lung transplantation. *J R Soc Med* 90 Suppl 31, 47-58 (1997).
751. Ruttens, D, Verleden, SE, Vandermeulen, E, Vos, R, van Raemdonck, DE, Vanaudenaerde, BM, *et al.* Body mass index in lung transplant candidates: a contra-indication to transplant or not? *Transplant Proc* 46, 1506-1510 (2014).
752. Korb-Savoldelli, V, Sabatier, B, Gillaizeau, F, Guillemain, R, Prognon, P, Begue, D, *et al.* Non-adherence with drug treatment after heart or lung transplantation in adults: a systematic review. *Patient Educ Couns* 81, 148-154 (2010).
753. Kulak, CAM, Cochenski Borba, VZ, Kulak, J & Ribeiro Custodio, M. Osteoporosis After Transplantation. *Current Osteoporosis Reports* 10, 48-55 (2012).
754. Detsky, AS, McLaughlin, JR, Baker, JP, Johnston, N, Whittaker, S, Mendelson, RA, *et al.* What is subjective global assessment of nutritional status? *JPEN J Parenter Enteral Nutr* 11, 8-13 (1987).
755. Weimann, A, Braga, M, Harsanyi, L, Laviano, A, Ljungqvist, O, Soeters, P, *et al.* ESPEN Guidelines on Enteral Nutrition: Surgery including organ transplantation. *Clin Nutr* 25, 224-244 (2006).
756. Tynan, C & Hasse, JM. Current nutrition practices in adult lung transplantation. *Nutr Clin Pract* 19, 587-596 (2004).
757. Tabarelli, W, Bonatti, H, Tabarelli, D, Eller, M, Muller, L, Ruttman, E, *et al.* Long term complications following 54 consecutive lung transplants. *Journal of Thoracic Disease*. 8, 1234-1244 (2016).
758. Hirche, TO, Knoop, C, Hebestreit, H, Shimmin, D, Sole, A, Elborn, JS, *et al.* Practical guidelines: lung transplantation in patients with cystic fibrosis. *Pulm Med* 2014, 621342 (2014).
759. Braun, AT & Merlo, CA. Cystic fibrosis lung transplantation. *Curr Opin Pulm Med* 17, 467-472 (2011).
760. Paul, S, Escareno, CE, Clancy, K, Jaklitsch, MT, Bueno, R & Lautz, DB. Gastrointestinal complications after lung transplantation. *J Heart Lung Transplant* 28, 475-479 (2009).

761. Lee, JT, Hertz, MI, Dunitz, JM, Kelly, RF, D'Cunha, J, Whitson, BA, *et al.* The rise of *Clostridium difficile* infection in lung transplant recipients in the modern era. *Clin Transplant* 27, 303-310 (2013).
762. Theunissen, C, Knoop, C, Nonhoff, C, Byl, B, Claus, M, Liesnard, C, *et al.* *Clostridium difficile* colitis in cystic fibrosis patients with and without lung transplantation. *Transpl Infect Dis* 10, 240-244 (2008).
763. Davis, CS, Shankaran, V, Kovacs, EJ, Gagermeier, J, Dilling, D, Alex, CG, *et al.* Gastroesophageal reflux disease after lung transplantation: pathophysiology and implications for treatment. *Surgery* 148, 737-744; discussion 744-735 (2010).
764. Raviv, Y, D'Ovidio, F, Pierre, A, Chaparro, C, Freeman, M, Keshavjee, S, *et al.* Prevalence of gastroparesis before and after lung transplantation and its association with lung allograft outcomes. *Clin Transplant* 26, 133-142 (2012).
765. Grass, F, Schafer, M, Cristaudi, A, Berutto, C, Aubert, JD, Gonzalez, M, *et al.* Incidence and Risk Factors of Abdominal Complications After Lung Transplantation. *World J Surg* 39, 2274-2281 (2015).
766. Lynch, JP, 3rd, Sayah, DM, Belperio, JA & Weigt, SS. Lung transplantation for cystic fibrosis: results, indications, complications, and controversies. *Semin Respir Crit Care Med* 36, 299-320 (2015).
767. Davidson, J, Wilkinson, A, Dantal, J, Dotta, F, Haller, H, Hernandez, D, *et al.* New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. *Transplantation* 75, Ss3-24 (2003).
768. Phuong-Thu, TP, Phuong-Mai, TP, Son, VP, Phuong-Anh, TP & Phuong-Chi, TP. New onset diabetes after transplantation (NODAT): an overview. *Diabetes, Metabolic Syndrome and Obesity*. 4, 175-186 (2011).
769. Kesiraju, S, Paritala, P, Rao Ch, UM & Sahariah, S. New onset of diabetes after transplantation - an overview of epidemiology, mechanism of development and diagnosis. *Transpl Immunol* 30, 52-58 (2014).
770. Park, SC, Yoon, YD, Jung, HY, Kim, KH, Choi, JY, Park, SH, *et al.* Effect of transient post-transplantation hyperglycemia on the development of diabetes mellitus and transplantation outcomes in kidney transplant recipients. *Transplant Proc* 47, 666-671 (2015).
771. Hackman, KL, Snell, GI & Bach, LA. Prevalence and predictors of diabetes after lung transplantation: a prospective, longitudinal study. *Diabetes Care* 37, 2919-2925 (2014).
772. Sharif, A & Cohney, S. Post-transplantation diabetes-state of the art. *Lancet Diabetes Endocrinol* 4, 337-349 (2016).
773. Brennan, AL, Geddes, DM, Gyi, KM & Baker, EH. Clinical importance of cystic fibrosis-related diabetes. *J Cyst Fibros* 3, 209-222 (2004).
774. Bradbury, RA, Shirkhedkar, D, Glanville, AR & Campbell, LV. Prior diabetes mellitus is associated with increased morbidity in cystic fibrosis patients undergoing bilateral lung transplantation: an 'orphan' area? A retrospective case-control study. *Intern Med J* 39, 384-388 (2009).
775. Herrero, JI, Benlloch, S, Bernardos, A, Bilbao, I, Castells, L, Castroagudin, JF, *et al.* Gastrointestinal complications in liver transplant recipients: MITOS study. *Transplant Proc* 39, 2311-2313 (2007).
776. Diaz, B, Gonzalez Vilchez, F, Almenar, L, Delgado, JF, Manito, N, Paniagua, MJ, *et al.* Gastrointestinal complications in heart transplant patients: MITOS study. *Transplant Proc* 39, 2397-2400 (2007).
777. Bunnapradist, S & Ambuhl, PM. Impact of gastrointestinal-related side effects on mycophenolate mofetil dosing and potential therapeutic strategies. *Clin Transplant* 22, 815-821 (2008).
778. Staatz, CE & Tett, SE. Pharmacology and toxicology of mycophenolate in organ transplant recipients: an update. *Arch Toxicol* 88, 1351-1389 (2014).
779. Zeltzer, SM, Taylor, DO & Tang, WH. Long-term dietary habits and interventions in solid-organ transplantation. *J Heart Lung Transplant* 34, 1357-1365 (2015).
780. Chan, LN. Drug-nutrient interactions in transplant recipients. *JPEN J Parenter Enteral Nutr* 25, 132-141 (2001).
781. Tsang, VT, Johnston, A, Heritier, F, Leaver, N, Hodson, ME & Yacoub, M. Cyclosporin pharmacokinetics in heart-lung transplant recipients with cystic fibrosis. Effects of pancreatic enzymes and ranitidine. *Eur J Clin Pharmacol* 46, 261-265 (1994).
782. Young, LR, Hadjiliadis, D, Davis, RD & Palmer, SM. Lung transplantation exacerbates gastroesophageal reflux disease. *Chest* 124, 1689-1693 (2003).
783. Davis, RD, Jr., Lau, CL, Eubanks, S, Messier, RH, Hadjiliadis, D, Steele, MP, *et al.* Improved lung allograft function after fundoplication in patients with gastroesophageal reflux disease undergoing lung transplantation. *J Thorac Cardiovasc Surg* 125, 533-542 (2003).
784. Hadjiliadis, D, Duane Davis, R, Steele, MP, Messier, RH, Lau, CL, Eubanks, SS, *et al.* Gastroesophageal reflux disease in lung transplant recipients. *Clin Transplant* 17, 363-368 (2003).
785. Abbassi-Ghadi, N, Kumar, S, Cheung, B, McDermott, A, Knaggs, A, Zacharakis, E, *et al.* Anti-reflux surgery for lung transplant recipients in the presence of impedance-detected duodenogastroesophageal reflux and bronchiolitis obliterans syndrome: a study of efficacy and safety. *J Heart Lung Transplant* 32, 588-595 (2013).
786. International Society for Heart and Lung Transplant. An International ISHLT/ATS/ERS Clinical Practice Guideline: Diagnosis and Management of Bronchiolitis Obliterans Syndrome. (The International Society for Lung and Heart Transplantation, Texas, USA., 2014). [http://ishlt.org/ContentDocuments/AN\\_INTERNATIONAL\\_ISHLT-ATS-ERS\\_CLINICAL\\_PRACTICE\\_GUIDELINE\\_DIAGNOSIS\\_AND\\_MANAGEMENT\\_OF\\_BRONCHIOLITIS\\_OBLITERANS\\_SYNDROME.pdf](http://ishlt.org/ContentDocuments/AN_INTERNATIONAL_ISHLT-ATS-ERS_CLINICAL_PRACTICE_GUIDELINE_DIAGNOSIS_AND_MANAGEMENT_OF_BRONCHIOLITIS_OBLITERANS_SYNDROME.pdf)
787. King, BJ, Iyer, H, Leidi, AA & Carby, MR. Gastroesophageal reflux in bronchiolitis obliterans syndrome: a new perspective. *J Heart Lung Transplant* 28, 870-875 (2009).





788. Wai-Kit, L, Burakoff, R, Goldberg, H, Feldman, N & Chan, W. Pre-lung transplant measures of reflux on impedance are superior to pH testing alone in predicting early allograft injury. *World J Gastroenterol* (2015).
789. Obayashi, PA. Food safety for the solid organ transplant patient: preventing foodborne illness while on chronic immunosuppressive drugs. *Nutr Clin Pract* 27, 758-766 (2012).
790. Medeiros, LC, Chen, G, Kendall, P & Hillers, VN. Food safety issues for cancer and organ transplant patients. *Nutr Clin Care* 7, 141-148 (2004).
791. Lund, BM & O'Brien, SJ. The occurrence and prevention of foodborne disease in vulnerable people. *Foodborne Pathog Dis* 8, 961-973 (2011).
792. Avery, RK & Michaels, MG. Strategies for safe living after solid organ transplantation. *Am J Transplant* 13 Suppl 4, 304-310 (2013).
793. World Health Organization. WHO Guidelines for Drinking - Water Quality - Fourth Edition. (2011). [http://apps.who.int/iris/bitstream/10665/44584/1/9789241548151\\_eng.pdf](http://apps.who.int/iris/bitstream/10665/44584/1/9789241548151_eng.pdf)
794. Silk, BJ, McCoy, MH, Iwamoto, M & Griffin, PM. Foodborne listeriosis acquired in hospitals. *Clin Infect Dis* 59, 532-540 (2014).
795. Goulet, V, Hebert, M, Hedberg, C, Laurent, E, Vaillant, V, De Valk, H, *et al.* Incidence of listeriosis and related mortality among groups at risk of acquiring listeriosis. *Clin Infect Dis* 54, 652-660 (2012).
796. World Health Organization and Food and Agriculture Organization of the United Nations. Risk assessment of *Listeria monocytogenes* in ready-to-eat foods. (WHO/FAO, Rome, Italy, 2004). <http://www.fao.org/docrep/010/y5394e/y5394e00.htm>
797. Fernandez-Sabe, N, Cervera, C, Lopez-Medrano, F, Llano, M, Saez, E, Len, O, *et al.* Risk factors, clinical features, and outcomes of listeriosis in solid-organ transplant recipients: a matched case-control study. *Clin Infect Dis* 49, 1153-1159 (2009).
798. Dale, K, Kirk, M, Sinclair, M, Hall, R & Leder, K. Reported waterborne outbreaks of gastrointestinal disease in Australia are predominantly associated with recreational exposure. *Aust N Z J Public Health* 34, 527-530 (2010).
799. Stallings, VA, Stark, LJ, Robinson, KA, Feranchak, AP, Quinton, H, Clinical Practice Guidelines on, G, *et al.* Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: results of a systematic review. *J Am Diet Assoc* 108, 832-839 (2008).
800. Ziessman, HA, Bonta, DV, Goetze, S & Ravich, WJ. Experience with a simplified, standardized 4-hour gastric-emptying protocol. *J Nucl Med* 48, 568-572 (2007).
801. Bloom, RD & Crutchlow, MF. Transplant-associated hyperglycemia. *Transplant Rev (Orlando)* 22, 39-51 (2008).
802. Park, JM, Lake, KD & Cibrik, DM. Impact of changing from cyclosporine to tacrolimus on pharmacokinetics of mycophenolic acid in renal transplant recipients with diabetes. *Ther Drug Monit* 30, 591-596 (2008).
803. McClave, SA, Taylor, BE, Martindale, RG, Warren, MM, Johnson, DR, Braunschweig, C, *et al.* Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.). *JPEN J Parenter Enteral Nutr* 40, 159-211 (2016).
804. Lidor, AO, Ensor, CR, Sheer, AJ, Orens, JB, Clarke, JO & McDyer, JF. Domperidone for delayed gastric emptying in lung transplant recipients with and without gastroesophageal reflux. *Prog Transplant* 24, 27-32 (2014).
805. Krishna, G, Moton, A, Ma, L, Savant, I, Martinho, M, Seiberling, M, *et al.* Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers. *Clin Ther* 31, 286-298 (2009).
806. MIMS Online. Posaconazole. (MIMS, Australia, 2016). <http://www.mims.com.au/>
807. MIMS Online. Tacrolimus. (MIMS, Australia, 2016). <http://www.mims.com.au/>
808. McGeeney, LM & Gatiss, GA. A survey of food safety information and foodborne infections post solid organ transplant. *Clinical Nutrition* 9, 195-199 (2014).
809. Kosa, KM, Cates, SC, Adams-King, J & O'Brien, B. Improving foodborne illness prevention among transplant recipients. *Health Promot Pract* 12, 235-243 (2011).
810. Cantu, E, 3rd, Appel, JZ, 3rd, Hartwig, MG, Woreta, H, Green, C, Messier, R, *et al.* J. Maxwell Chamberlain Memorial Paper. Early fundoplication prevents chronic allograft dysfunction in patients with gastroesophageal reflux disease. *Ann Thorac Surg* 78, 1142-1151; discussion 1142-1151 (2004).
811. Ebeling, PR. Transplantation osteoporosis. *Curr Osteoporos Rep* 5, 29-37 (2007).
812. Lakey, WC, Spratt, S, Vinson, EN, Gesty-Palmer, D, Weber, T & Palmer, S. Osteoporosis in lung transplant candidates compared to matched healthy controls. *Clin Transplant* 25, 426-435 (2011).
813. Stein, EM & Shane, E. Vitamin D in organ transplantation. *Osteoporos Int* 22, 2107-2118 (2011).
814. The Agency for Clinical Innovation and the Gastroenterological Nurses College of Australia. A Clinician's Guide: Caring for people with gastrostomy tubes and devices from pre-insertion to ongoing care and removal. (The Agency for Clinical Innovation and the Gastroenterological Nurses College of Australia, Australia, 2014). [https://www.aci.health.nsw.gov.au/\\_data/assets/pdf\\_file/0017/251063/gastrostomy\\_guide-web.pdf](https://www.aci.health.nsw.gov.au/_data/assets/pdf_file/0017/251063/gastrostomy_guide-web.pdf)
815. Collins, K., Gaffney, L, Tan, J, Roberts, S & Nyulasi, I. Gastrostomy guidelines: a rapid review. (The Sax Institute for the NSW Agency for Clinical Innovation, Australia, 2013). <https://www.saxinstitute.org.au/wp-content/uploads/Gastrostomy-guidelines-a-rapid-review.pdf>

816. Davies, BW, Watson, AR, Coleman, JE & Rance, CH. Do gastrostomies close spontaneously? A review of the fate of gastrostomies following successful renal transplantation in children. *Pediatr Surg Int* 17, 326-328 (2001).
817. Janik, TA, Hendrickson, RJ, Janik, JS & Landholm, AE. Analysis of factors affecting the spontaneous closure of a gastrocutaneous fistula. *J Pediatr Surg* 39, 1197-1199 (2004).
818. Wyrick, DL, Bozeman, AP, Smith, SD, Jackson, RJ, Maxson, RT, Kelley, KR, *et al.* Persistent gastrocutaneous fistula: factors affecting the need for closure. *J Pediatr Surg* 48, 2506-2510 (2013).
819. Stephenson, A, Brotherwood, M, Robert, R, Durie, P, Verjee, Z, Chaparro, C, *et al.* Increased vitamin A and E levels in adult cystic fibrosis patients after lung transplantation. *Transplantation* 79, 613-615 (2005).
820. Lyu, DM & Zamora, MR. Medical complications of lung transplantation. *Proc Am Thorac Soc* 6, 101-107 (2009).
821. Bloom, RD & Reese, PP. Chronic kidney disease after nonrenal solid-organ transplantation. *J Am Soc Nephrol* 18, 3031-3041 (2007).
822. Kench, A, Graham, C, Crowder, T, Matson, A & King, S. Nutrition management of CF in Australasia - changes since 2015. (unpublished 2016).

#### (FOOTNOTES)

1 *There is ongoing debate regarding conversion factors for carotenoids. Australia and NZ have maintained traditional conversion rates more aligned with sources of carotenoids in our diet, whereas conversion rates are double in the US. Note 1 RAE = 1 µg retinol= 12 µg β-Carotene*













**The Thoracic Society of Australia and New Zealand Ltd**

Suite 405, Level 4,

5 Hunter Street,

Sydney NSW 2000

**P** +61 2 9222 6200

**F** +61 2 9221 0438

**E** [info@thoracic.org.au](mailto:info@thoracic.org.au)

**[www.thoracic.org.au](http://www.thoracic.org.au)**